

CURRICULUM VITAE

Sanjay Gupta, Ph.D., M.S.

**Professor of Urology
Carter Kissell Endowed Chair in Urologic Oncology
Department of Urology
Case Western Reserve University**

**Research Director
The Urology Institute
University Hospitals Cleveland Medical Center**

**Research Health Scientist
Department of Veterans Affairs
Louis Stokes VA Medical Center**

Updated April 01, 2019

PERSONAL INFORMATION

Name: Sanjay Gupta
Citizenship: United States of America
Home Address: 6582 Hidden Woods Trail
Mayfield Heights, Ohio-44143
Phone: (440) 229-2679

RANK/TITLE

Professor & Research Director
Carter Kissell Endowed Chair
Office address: Department of Urology
Case Western Reserve University
2109 Adelbert Road
Wood Research Tower; RTG-01
Cleveland, Ohio 44106-4931
Phone: (216) 368-6162 (Work)
(440) 915-4692 (Cell)
Fax: (216) 368-0213
E-mail: sanjay.gupta@case.edu
Web-site: <http://casemed.case.edu/dept/urology/BioGupta.cfm>

Clinical Office address: The Urology Institute
University Hospitals Cleveland Medical Center
11000 Euclid Avenue
Lakeside 4th floor
Cleveland, Ohio-44106
Email: SGuptax7@UHhospitals.org

Other address: Research Scientist
Louis Stokes VA Medical Center
Room#217
10701 East Blvd, Cleveland, OH 44106
Phone: (216) 791-3800 [Ext. 5083]
E-mail: sanjay.gupta3@va.gov

RESEARCH AND PROFESSIONAL APPOINTMENTS

2001-2002 Instructor, Dermatology, Case Western Reserve University, Cleveland, Ohio
2002-2003 Instructor, Urology, Case Western Reserve University, Cleveland, Ohio
2003-2006 Assistant Professor, Urology, CWRU School of Medicine & Division of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, Ohio
2006-2012 Associate Professor, Urology and secondary appointment in the Department of Nutrition, Case Western Reserve University School of Medicine & Division of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, Ohio
2008-2012 Carter Kissell Associate Professor of Urology, Department of Urology, Case Western Reserve University, Cleveland, Ohio
2008-present Research Director, Department of Urology, Case Western Reserve University, Cleveland, Ohio
2010-2012 Carter Kissell Associate Professor of Urology (tenured), Department of Urology, Case Western Reserve University, Cleveland, Ohio
2012-present Carter Kissell Endowed Chair in Urology, Department of Urology, Case Western Reserve University, Cleveland, Ohio
2012-present Professor, Department of Urology with secondary appointment in the Department of Nutrition, Case Western Reserve University School of Medicine & Division of General Medical Sciences, Case Comprehensive Cancer Center, Cleveland, Ohio
2016-present Research Director, The Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio

2015-present Health Research Scientist, Louis Stokes VA Medical Center, Cleveland, Ohio

EDUCATION

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1981-83	B.S. Chemistry, Botany, Zoology	Lucknow University, Lucknow, India
1983-84	B.S. (<i>Honors</i>) Chemistry	Lucknow University, Lucknow, India
1984-85	M.S. (<i>Special</i>) Inorganic Chemistry	Lucknow University, Lucknow, India
1988-92	Ph.D. Chemistry	Avadh University, Faizabad, India

Thesis title: Evaluation of Chelating Drugs in Metal Poisoning

DOCTORAL AND POSTDOCTORAL TRAINING

1988-1991	Research Fellow, Industrial Toxicology Research Center, India
1992-1993	Senior Research Fellow, Industrial Toxicology Research Center, India
1993-1995	Senior Research Assistant, King George's Medical College, India
1996-1997	Research Associate, Industrial Toxicology Research Center, India
1997-1998	Post-doctoral Fellow, Dermatology, Case Western Reserve University, Cleveland, Ohio
1999-2000	Research Associate, Dermatology, Case Western Reserve University, Cleveland, Ohio
2000-2001	Senior Research Associate, Dermatology, Case Western Reserve Univ., Cleveland, Ohio

MEMBERSHIP/SOCIETIES

2006-present	American Association for the Advancement of Science (AAAS), USA
1999-present	American Association for Cancer Research (AACR), USA
2002-present	American Urological Association (AUA), USA
2002-present	Society for Basic Urologic Research (SBUR), USA
2012-present	American Society of Clinical Oncology (ASCO), USA

RESEARCH EXPERIENCE

Multidisciplinary areas of prostate, breast and bladder carcinogenesis, cancer biomarkers, cancer therapeutics and drug repurposing, cancer chemoprevention, diet nutrition and cancer, drug delivery, toxicology, oncogenes, cell signaling, epigenetic and cancer prevention, inflammatory responses, cancer stem cells, and clinical research

RESEARCH INTERESTS

- Molecular mechanism(s) of prostate and bladder carcinogenesis
- Role of inflammation in promoting prostate and bladder cancer
- Biomarker(s) for detection and prognosis of prostate cancer
- Artificial intelligence and machine learning for cancer prognosis
- Identification and characterization of prostate cancer stem cells
- Epigenetic mechanisms of gene silencing in prostate/bladder cancer and its reversal by dietary agents
- Molecular targets for prevention and treatment of prostate cancer
- Chemoprevention of prostate/bladder cancer by naturally occurring and/or synthetic compounds
- Drug repurposing, mechanism(s) of action with non-chemotherapeutic agents
- Clinical trials with promising agents and their combinations

AWARD/HONORS

Year Award

1996	Research Associateship Award from the Council of Scientific and Industrial Research, India
1997	Nitric Oxide Grant Travel Award for work presentation at the Nitric Oxide Society Grant, Japan
1998	American Society for Photobiology Travel Award for research presentation
1998	Society of Toxicology Travel Award for research presentation
1999	American Society for Photobiology Travel Award for research presentation
1999	AACR-Intergen Young Investigator Award for meritorious work in cancer research

2000 Albert M Kligman Fellowship, Meritorious research work in skin cancer

2001 The OCHA(Tea) Pioneer Academic Grant Award, Japan to conduct pioneering research on green tea

2005 Prostate Cancer Biomarkers Meeting Award for pioneering work on prostate cancer biomarkers

2010 Society for Basic Urologic Research (SBUR) Fall Meeting Travel Award for research presentation

2013 Biomedical Graduate Student Symposium Award to Melissa Babcook for Best Poster Presentation

2013 Scientific Poster Presentation Award to Melissa Babcook at the Case Comprehensive Cancer Center Retreat

2013 Graduate Student Research Award to Melissa Babcook at the 2013 Research Showcase CWRU

2014 American Asian Scientist Award from Society of SAASCR for prestigious research

2014 Graduate Student Research Award to Jeniece Montellano at the 2014 Research Showcase CWRU

2015 Society for Basic Urologic Research (SBUR) Fall Meeting Travel Award for research presentation in Fort Lauderdale, FL

2015 Doctoral Excellence Award Winner 2015 in the Department of Nutrition to Dr. Melissa A. Babcook

2016 Associations of Indian Physicians of Northeast Ohio (AIPNO) Travel Award for presentation at the 2016 Annual AACR Meeting in New Orleans, LA

2016 DPD Deficiency Foundation Award for poster presentation at the AACR Annual Meeting

2106 Bio Basic Inc. Travel Award for poster presentation at 2016 AUA Annual Meeting

2016 American Urological Association Travel Award for research presentation at the 2016 AUA Annual Meeting in San Diego, CA

2016 Associations of Indian Physicians of Northeast Ohio (AIPNO) for poster presentation

2017 Graduate Student Research Award to Aditi Goel at the 2017 Research Showcase CWRU

2017 Graduate Student Research Award to Michael Glover at the 2017 Research Showcase CWRU

2017 Alkali Scientific Inc. Travel Award for research presentation at the 2017 Annual AACR Meeting in Washington DC.

2017 Travel support from Mr. Jay Narayanan, SAP BI/BOBJ Architect, Dart Container Corporation for presentation at 2017 Annual AUA Meeting in Boston, MA

2017 Travel support from Dr. Sanjay Chowdhary, MD. Fairview Hospital, Cleveland Clinic Health System for presentation at the 2017 Annual AUA Meeting in Boston, MA

2017 Travel support from Mr. Mathew Varghese, Global Data for presentation at the 2017 Annual AUA Annual Meeting in Boston, MA

2017 Prostate Network Award, Kansas, to Dr. Eswar Shankar for Poster Presentation at the SBUR Fall Symposium, Tampa FL

2017 Associations of Indian Physicians of Northeast Ohio (AIPNO) Award to Dr. Eswar Shankar for poster presentation

2017 Associations of Indian Physicians of Northeast Ohio (AIPNO) Award to Michael Glover for poster presentation

2018 Award from Faith Medical Associates, Inc. supporting the 2018 American Association for Cancer Research (AACR) Annual Meeting registration in Chicago IL

2018 Travel Award to Dr. Eswar Shankar from SEWA USA for attending the 2018 American Association for Cancer Research (AACR) Annual Meeting in Chicago IL

2018 Epigenomes Travel Award to Dr. Eswar Shankar for poster presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting in Chicago IL

2019 Travel Support from Case Comprehensive Cancer Center (CCCC) for poster presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta GA

2019 Travel Award from SEWA USA to Dr. Eswar Shankar for attending Society for Basic Urologic Research (SBUR) Spring Meeting in Chicago IL

REVIEW COMMITTEE/PROFESSIONAL ACTIVITIES

2002	Member, NIH, Special Emphasis Panel on "Cooperative Grants for Nutritional Modulation of Genetic Pathways Leading to Cancer"
2003-2005	Member, NIH, Special Emphasis Panel on Cancer Prevention Research Small Grant Program, 2003-2005
2003-2005	Member, NIH, Special Emphasis Panel on Small Grants Program for Cancer Epidemiology
2004	Member, NIH, Special Emphasis Panel on Program Projects submitted to Sub-committee E on Cancer Epidemiology, Prevention and Control
2004	Reviewer, Abstract submitted in 11 th Annual Meeting of the Society for Free Radical Biology and Medicine
2004	Member, NIH, Special Emphasis Panel of Oncology (ZRG1 ONC-B 03), Chemoprevention of Prostate Cancer
2005	Member, NIH/NCI, Special Emphasis Panel on Program Projects
2005	Member, NIH/NCI, Special Emphasis Panel of Signaling Pathways and Tumorigenesis ZRG1ONC-B
2005	Ad-hoc Member, Special Emphasis on Cancer Prevention Research and Cancer Epidemiology Small Grant Program
2005	Reviewer, Abstract submitted in 12 th Annual Meeting of the Society for Free Radical Biology and Medicine
2006	Ad-hoc Reviewer, Council ZRG1 ONC-T 04 on cancer prevention, National Institutes of Health/National Cancer Institute
2006	Reviewer Scientist, Department of Defense Prostate Cancer Training Grants
2006	Reviewer Scientist, Department of Defense Breast Cancer Training Grants
2006	Ad-Hoc Reviewer, NCI Special Emphasis Panel ZCA SRRB-3 (O1) on Tumor Microenvironment Network
2005-2008	Ad-hoc Member, NIH/NCI, Chemo/Dietary Prevention (CDP) Study Section
2007	Reviewer, NIH/NCI, Special Emphasis Panel of Oncology (ZRG1 ONC-B 03), Molecular Targets for Cancer Prevention
2007	Reviewer Scientist, Department of Defense Breast Cancer Training Grants
2007	Reviewer, NCI Special Emphasis Panel of SPORE in Lymphoma, Prostate, Breast, Skin, Leukemia and GI Cancers (ZCA1 RPRB-M (J1), 2007
2007	Reviewer, NIH/NCI, Special Emphasis Panel of Oncology (ZRG1 ONC-W 91A), R15 Grants on Basic and Translational Research
2008	Grant Reviewer, Bankhead-Coley Cancer Research Program, Florida Department of Health
2008	Reviewer, NIH/NCI, Special Emphasis Panel of Oncology (ONC-W91L), R15 Grants on Basic and Translational Research
2008	Reviewer Scientist, Department of Defense Breast Cancer Training Grants
2008	Reviewer, NIH/NCI, Special Emphasis Panel, PO1 (ZCA1 RPRB-M, J2) Epidemiology, Prevention and Control
2009	Reviewer, NIH/NCI, Special Emphasis Panel on Prevention Control and Population Sciences (ZCA1 GRB-P, M1)
2009	Scientific Reviewer, Department of Defense, Breast Cancer Research Review Panel, Pre- and Post-doctoral Fellowship
2009	Scientific Reviewer, Department of Defense, Prostate Cancer Research Review Panel on Clinical Health Sciences-Epidemiology (CHS-EPI)
2010	Scientific Reviewer, Department of Defense, Prostate Cancer Research Review Panel on Detection, Diagnosis and Prognosis
2010	Reviewer, NIH/NCI, Special Emphasis Panel on EDRN Biomarker Development Lab
2010	Scientific Reviewer, Department of Defense, Prostate Cancer Research Review Panel on Clinical Experimental Therapeutics (CET)
2011	Reviewer, NIH/NCI, Special Emphasis Panel (ZRG1-OTC-W-12), Research grants/R&D Effort [type 2 R42 (STTR) and type 2 R44 (SBIR) applications
2012	Scientific Reviewer, Department of Defense, Prostate Cancer Research Review Panel on Prevention, Treatment and Epidemiology

2012 Reviewer, NIH/NCI, Special Emphasis Panel, Research grants/R&D Effort [type 2 R42 (STTR) and type 2 R44 (SBIR) applications]

2012 Scientific Reviewer, Department of Defense, Prostate Cancer Research Review Panel on Exploration grants

2009-2012 Permanent Member, NIH/NCI, Chemo/Dietary Prevention (CDP) Study Section

2012 Reviewer, NCI/NIMH and Health Disparity Special Emphasis Panel ZMD1 MLS (02)

2013 Reviewer, National Science Center, Krakow, Poland

2013 Reviewer, Austrian Science Fund, Vienna, Austria

2013 Reviewer, NIH Special Emphasis Panel - ZRG1 OTC-C (02) Cancer Prevention Study Section

2013 Reviewer, NIH/NCI, Special Emphasis Panel (ZRG1-OTC-W-12), Research grants/R&D Effort [type 2 R42 (STTR) and type 2 R44 (SBIR) applications]

2014 Reviewer, ZRG1 MOSS-C56 panel to review NIH Director's New Innovator Award (DP2)

2014 Reviewer, Special Emphasis Panel/Scientific Review Group 2014/05 ZCA1 SRLB-5 (M2) S meeting

2014 Reviewer, CSR/NIH ranking pilot grants

2014 Reviewer and Co-Chair, ZRG1 OTC-C (02) Cancer Therapeutics Study Section

2014 Reviewer, NIH/NCI, CDDT (ZRG1 OTC-T10) Study Section

2015 Member, NCI Expert Panel Meeting, The Partnership for Native American Cancer Prevention, Tucson, AZ

2015 Reviewer, NIH/NCI, ZCA1 PCRB CO1 Study Section

2015 Reviewer, Program Project (P01) NIH/NCI ZCA1 (RPRB-7) Study Section

2015 Reviewer, NIH/NCI SPORE ZCA1 (RPRB-7 J1) Study Section

2015 Reviewer, ZAT1-HS-19 Center of Excellence for Research on CAM (CERC) Study Section

2015 Reviewer, MRC UK SBS, North Star House, North Star Avenue, Swindon, SN2 1FF on grant application "The effect of metformin in prostate cancer progression and bone metastases"

2015 Reviewer, Movember Discovery Grant Review Panel, Prostate Cancer, Canada

2015 Reviewer, NCI Special Emphasis Panel (SEP) Research partnership grant applications received in response to PAR-14-152, Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) and Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)

2015 Reviewer, Ministry of Health, Direction for Scientific Research and Health Innovation, Italy

2015 Reviewer, National Science Foundation-NSF Electronic Proposal NSF's CAREER Solicitation

2015 Grant Reviewer, Morehouse School of Medicine- Atlanta GA, Morehouse School of Medicine/Tuskegee University/UAB Comprehensive Cancer Center Partnership (MSM/TU/UAB CCC)

2016 Reviewer, Special Emphasis Panel/Scientific Review Group 2016/05 ZRG1 MOSS-C (56) R meeting

2016-2018 Grant Reviewer, National Science Center, Poland

2016 Grant Reviewer, Sultan Qaboos University, Oman

2016 Reviewer, ZDK1 GRB-J O2 Developmental Centers for Interdisciplinary Research in Benign Urology

2016 Reviewer, NIH R01 grant proposals-Independent Review conducted by University of Wisconsin-Madison

2016 Reviewer, NCI Clinical and Translational R21: SEP-2, 2017/01 ZCA1 SRB-X (J2) S

2016 Reviewer, NCI Clinical and Translational R21: SEP-6, 2017/01 ZCA1 RPRB-7 (J2) S

2016 Reviewer, Hormonal and Chemotherapy Sensitizing Agents for Prostate Cancer – Special Focus on Targeting Cell Plasticity" and "Cancer Sensitizing Agents for Chemotherapy"

2017 Reviewer, ZRG1 MOSS-R (56) R-RFA-RM-16-004: NIH Director's New Innovator Award

2017 Grant Reviewer, Italian Ministry of Health, Italy

2017 Reviewer, NCI Clinical and Translational Exploratory/Developmental Studies (R21)

2017 Reviewer, Special Emphasis Panel/Scientific Review Group 2017/08 ZMD1 MLS (O1) R meeting NIMHD Research Centers in Minority Institutions (RCMI) (U54)

2017 Reviewer, National Science Foundation (NSF) National Science Foundation, 4201 Wilson Boulevard, Arlington, VA 22230

2017 Reviewer, NCI Clinical and Translational Exploratory/Developmental Studies (R21) Special Emphasis Panel/Scientific Review Group 2017/10 ZCA1 TCRB-V (O1) S meeting

2017 Reviewer, Special Emphasis Panel/Scientific Review Group 2018/01 ZCA1 TCRB-W (J1) S meeting

2018 Reviewer, Pennsylvania Department of Health (ORAU) peer review of grants on prostate cancer

2018 Reviewer, NCI P20 applications on Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPORES)

2018 Reviewer, NCI Small Grants Program for Cancer Research, Omnibus R03 Clinical Trial Optional

2018 Reviewer, SEP for R01 applications in Chemo/Dietary Prevention and Cancer Biomarkers

COUNCIL AND COMMITTEES

2005 Advisory Committee, International Symposium on Diet in Causation and Prevention of Cancer

2006-2008 Member, Department Committee on Appointments, Promotions and Tenure

2006 Member Training Faculty for Case Comprehensive Cancer Center's K12 Clinical Oncology Research Career Development Program

2006-2009 Member Steering Committee, Human Tissue Procurement Facility at Cancer Center Tissue Procurement and Histology Core, Case Western Reserve University, University Hospitals of Cleveland

2007-2008 Judge, SOURCE Symposium & Poster Session, Undergraduate Education Program, Case Western Reserve University

2006-2008 Judge, Science Program and Fair Projects, Mayfield High School, Cleveland

2008 Organizer/Advisory Committee, International Symposium on "Novel Strategies for Targeted Prevention and Treatment of Cancer" December 19-20, 2008 at Jawaharlal Nehru University, New Delhi, India

2010 Member, Scientific Advisory Committee, International Cancer Research Symposium 2010: "Defining & Translating Science for Disease Prevention and Treatment" December 20-22, 2010 at Rajiv Gandhi Biotechnology Center (RGBC), Thiruvananthapuram, India

2008-2011 Chairman, Department Committee on Appointments, Promotions and Tenure, Department of Urology, Case Western Reserve University

2009-present Member, Protocol Review and Monitoring Committee (PRMC), University Hospitals Case Medical Center and Case Comprehensive Cancer Center

2012-present Chairman, Department Committee on Appointments, Promotions and Tenure, Department of Urology, Case Western Reserve University

2013-present Member, Faculty Senate Committee, School of Medicine, Case Western Reserve University

2013-2014 Member, Program Technical Committee, 3rd Science One Conference on Drug Discovery & Development, Dubai January 21-23, 2014

2014-2015 Member, Faculty Search Committee, Biomedical Engineering/Case Comprehensive Cancer Center

2014-2015 Member, Urology Chair Search Committee, CWRU School of Medicine & The Urology Institute

2015-2016 Member, Urology Faculty Search Committee, CWRU School of Medicine & The Urology Institute

2015-2016 Member, Organizing Committee, International Conference on Cancer Care and Cure 2016, Dubai, UAE December 01-02, 2016

2015-2016 Advisory Board Member, NEO'16 International Cancer Conference, Hyderabad, India February 06, 2016

2015 Member, Organizing Committee, International Conference on Prostate Cancer, Florida, USA on June 22-24, 2015

2015 Member, Cancer Informatics Faculty Search Committee, Department of Biomedical Engineering

2015 Member Organizing Committee, Global Cancer Summit-2015 with the theme Frontiers in Oncology: Genetics, Diagnostics and Therapeutics, Indian Institute of Sciences, Bangalore, India on November 18-20 2015

2015 Member, Scientific Organizing Committee, Cancer Global Summit -Middle East in Dubai, UAE from October 5-7, 2015

2015 Poster Judge, Rustbelt RNA Meeting-RRM-2015 Poster Session in Sawmill Creek, Ohio October 23-24, 2015

2016 Member, Society for Basic Urologic Research (SBUR) Membership Committee

2016	Member, Organizing Committee Cancer Care-2016 Associate Project Coordinator - Cancer Care 2016; Clyto Access Inc. (APAC Operations)
2016	Member, Organizing Committee for 2016 conference 13th Global Summit on Cancer Therapy, Dubai UAE, October 17-19, 2016
2016	Member, Organizing Committee, International Conference on Integrative Medicine and Nutrition, in Atlanta, GA November 28-29, 2016
2016	Judge Associations of Indian Physicians of Northeast Ohio (AIPNO)'s 4th Research Showcase at Cleveland Convention Center, October 22, 2016
2017	Member Organizing Committee, Gavin Conferences-International Conference on Oncology and Cancer Prevention, at Dubai, UAE, May 29-31, 2017
2017	Member, Organizing Committee, International Conference on Oncology and Cancer Prevention, Dubai, UAE, May 22-24, 2017
2017	Member, Organizing Committee, 26th World Cancer Convention, at Dubai, UAE, November 27-28, 2017
2017	Chairman, Society for Basic Urologic Research (SBUR) Membership Committee 2017-2018
2018	Member, Organizing Committee, International Conference on Biomarkers and Cancer Targets, Dubai UAE, July 16-17, 2018
2018	Member, Organizing Committee, International Conference on Cancer Diagnosis & Treatment, Oslo, Norway August 2-3, 2018
2018	Member, Organizing Committee, 2nd International Conference and Exhibition on Genome Science, San Diego, CA November 26-28, 2018
2017-present	Member, Louis Stokes Veteran Administration Medical Center, IACUC Committee
2019	Member Steering Committee, Human Tissue Procurement Facility at Cancer Center Tissue Procurement and Histology Core, Case Western Reserve University, University Hospitals Cleveland Medical Center
2019	Member, Program Committee, World Congress on Hematology and Oncology, Paris, France, November 25-26, 2019
2019	Member, Program Committee, International Conference on Cancer and Oncotherapy, Berlin, Germany, November 11 - 13, 2019
2019	Member, Case Western Reserve University, School of Medicine, Nomination and Election Committee,
2018-2021	Member, Case Western Reserve University, School of Medicine, Committee on Appointments, Promotions and Tenure (CAPT)

TEACHING EXPERIENCE

Faculty Trainee:

2005-2008	Lee E Ponsky, MD, K12 Clinical Oncology Research Career Development Program, Case Comprehensive Cancer Center
2013-2015	Lan Lu, PhD, K12 NIDDK Urology Research Career Development Program, Department of Urology
2009-2015	Sanjeev Shukla, PhD, Assistant Professor, Department of Urology, CWRU
2015-2018	Sanjeev Shukla, PhD, Research Scientist, Department of Pathology, CWRU
2017-present	Ata Abbas, PhD, Adjunct Assistant Professor, Cleveland Clinic Foundation, Cleveland, Ohio
2019-present	Eswar Shankar, PhD, Research Scientist, Department of Urology, CWRU

T32 Training Advisor:

2012-2013	Matthew Maurice, MD acting researcher co-advisor during his research year of residency
2012-2014	Jonathan Kenyon, PhD, post-doctoral advisor for NIH-funded T32 fellowship
2014-2015	Melissa A Babcook, PhD, post-doctoral advisor for NIH-funded T32 fellowship
2015-2017	Jon Whitney, PhD post-doctoral advisor for NIH-funded T32 fellowship

Thesis Supervisor/Co-supervisor:

1994-1995	Sanjay Pradhan, Ph.D. Student, Industrial Toxicology Research Center, India
-----------	---

1998-2002	Kedar Hastak, Ph.D. Student, Case Western Reserve University, Cleveland, Ohio
2008-2009	Cherry Nasr Kamel Serga, Visiting Scholar and Ph.D. candidate, Suez Canal University Hospital, Ismailia, Egypt
2008-2010	Akbar Nawab, Department of Environmental Sciences, Ambedkar University, Lucknow, India
2012-2013	Gauri Deb, Full Bright Graduate Student Scholar, Indian Institute of Technology, India
2009-2015	Melissa Babcock, Department of Nutrition, Case Western Reserve University, Cleveland, Ohio
2014-2016	George Lee, Research Co-Mentor, NIH-K01 Career Development award in Big Data Biomedical Sciences
2017-present	Patrick Leo, Research Co-Advisor, Master's Program, Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio

Thesis Evaluation/Advisory Committee:

2007	Ester Hang Zhou, Department of Epidemiology & Biostatistics "Treatment patterns and treatment outcomes for prostate cancer patients: An evaluation from individual to population"
2008-2010	Hesheng Wang, Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio
2008-2013	Tonibelle N Gatbonton, Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio
2013	External Appraiser, Master of Science, Final Oral Examination of Xianfeng Ge, University of Toronto, Toronto, ON and Sunnybrook Hospital, Toronto, Canada
2013	External Appraiser, Master of Science Final Oral Examination of Benjamin Mora, University of Toronto, Toronto, ON and Sunnybrook Hospital, Toronto, Canada
2014	External Appraiser, Doctor of Philosophy (Ph.D.) degree of M. Arokia Vijaya Anand, Annamalai University, Annamalai Nagar, India
2015	External Appraiser, Doctor of Philosophy (Ph.D.) degree of Natalie Venier, University of Toronto, Toronto, ON and Sunnybrook Hospital, Toronto, Canada
2015	External Appraiser, Doctor of Philosophy (Ph.D.) degree of Tarun Tyagi, Bharathiar University, Coimbatore, India
2015	External Appraiser, Doctor of Philosophy (Ph.D.) degree of J. Kalamathi, Bharathiar University, Coimbatore, India
2016	External Appraiser, Thesis Reviewer, Master of Science degree of Michelle Judith Mayer, Institute of Medical Science University of Toronto, Canada
2016	External Appraiser, Doctor of Philosophy (Ph.D.) degree of G. Annamalai, Annamalai University, Annamalai Nagar, India
2016	External Appraiser, Doctor of Philosophy (Ph.D.) degree of Sweta Sanguri, Institute of Nuclear Medicine and Allied Sciences, DRDO, Delhi, India
2017	External Appraiser, Doctor of Philosophy (Ph.D.) of Nazia Nazam, Aligarh Muslim University, Aligarh, India
2017	External Appraiser, Doctor of Philosophy (Ph.D.) of Jey Sabith Ebron, Cleveland, State University, Cleveland, Ohio
2017	External Appraiser, Doctor of Philosophy (Ph.D.) of Vijay Singh, Bharathiar University, Coimbatore, India
2017	External Appraiser, Doctor of Philosophy (Ph.D.) of M. Krishnaveni, Annamalai University, Annamalai Nagar, India
2017	External Appraiser, Doctor of Philosophy (Ph.D.) of Savita Singh, Cleveland, State University, Cleveland, Ohio
2017	External Appraiser, Doctor of Philosophy (Ph.D.) of Anita Sahu, Bharathiar University, Coimbatore, India
2017	External Appraiser, Doctor of Philosophy (Ph.D.) of Ahmed Haddad, Graduate Department of Institute of Medical Science, University of Toronto, Canada
2018	External Appraiser, Master Thesis Evaluation (MS) of Ms. Domenica Roberto, Graduate Department of Institute of Medical Science, University of Toronto, Canada
2019	External Appraiser, Doctor of Philosophy (Ph.D.) of Jenhinlalkhosh J.P., Bharathiar University, Coimbatore, India

Post-doctoral/Ph.D./MD Trainees:

1994-1995	Rahul R Mohan, Ph.D., Post-doctoral fellow, King George's Medical College, India
1998-1999	Mayank Srivastava, Ph.D., Post-doctoral fellow, Case Western Reserve University
1999-2001	Kazuko Sakamoto, Ph.D., Post-doctoral fellow, Case Western Reserve University
1999-2002	Farrukh Afaq, Ph.D., Post-doctoral fellow, Case Western Reserve University
2000-2002	Vaqr M Adhami, Ph.D., Post-doctoral fellow, Case Western Reserve University
2000-2002	Tajamul Hussain, Ph.D., Post-doctoral fellow, Case Western Reserve University
2003	Mamduh Mohamad, M.D., Exchange Visitor, Case Western Reserve University
2004	Bilal Bin Hafeez, Ph.D., Post-doctoral fellow, Case Western Reserve University
2005	Deendayal Patel, Ph.D., Post-doctoral fellow, Case Western Reserve University
2005	Ailin Zhang, Ph.D., Research scholar, Case Western Reserve University
2005-2006	Quanjian Yan, Ph.D., Post-doctoral fellow, Case Western Reserve University
2006-2012	Eugene (Yevgen) Vykhovanets, MD, Ph.D. Case Western Reserve University
2006-2007	Parminder Kaur, Ph.D., Post-doctoral fellow, Case Western Reserve University
2002-2007	Sanjeev Shukla, Ph.D., Post-doctoral fellow, Case Western Reserve University
2005-2008	Mitali Pandey, Ph.D., Post-doctoral fellow, Case Western Reserve University
2005-2008	Janmejai Kumar Srivastava, Ph.D. Post-doctoral fellow, Case Western Reserve University
2006-2007	Thangaiyan Rabi, Ph.D., Post-doctoral fellow, Case Western Reserve University
2007-2008	Ata Abbas, Ph.D., Post-doctoral fellow, Case Western Reserve University
2009-2013	Natrajan Bhaskaran, Ph.D., Post-doctoral fellow, Case Western Reserve University
2009-2010	Haripaul Sharma, Ph.D., Post-doctoral fellow, Case Western Reserve University
2009-2013	Vijay S Thakur, Ph.D., Senior Research Associate, Case Western Reserve University
2014-2015	Qiqi He, M.D., Visiting Scholar, Lanzhou University Second Hospital, China
2009-2019	Eswar Shankar, Ph.D., Post-doctoral fellow, Case Western Reserve University
2009-2018	Rajnee Kanwal, Ph.D., Post-doctoral fellow, Case Western Reserve University
2017	Anupam Chatterjee, Ph.D., Visiting Faculty, North Eastern Hill University, Shillong, India
2016-present	Andrew Blum, M.D., Research Mentor, Louis Stokes VA Medical Center
2019-present	Reem Elagooz, M.D., Research Scholar, Department of Clinical Pathology, Assiut University, Egypt
2019-present	Malek Alassfar, M.D., Research Scholar, University of Damascus, Damascus, Syria

Graduate/Undergraduate Students:

2002	Shawn Trokhan, Medical Student, Summer trainee, Case Western Reserve University
2003	Matthew F Hirschfeld, Graduate Student, Summer trainee, Case Western Reserve University
2004	Tanuja Pillai, Undergraduate Student, Summer trainee, Case Western Reserve University
2007	Donald J Harvey, Medical Student, Summer trainee, Case Western Reserve University
2008	Sarita Gautam, B.S., Graduate Student, Summer trainee, Case Western Reserve University
2009	Karishma Gupta, Undergraduate Student, Summer trainee, Case Western Reserve University
2011	Rachel Heim, Undergraduate Student, Project Advisor, Silber Student Research Fellowship
2012	Emmanuel Tavares, Undergraduate Student, Project Advisor and Trainer, Case Western Reserve University
2013	Christine Z Oak, Undergraduate Student, Project Advisor and Trainer, Case Western Reserve University
2014	Prithvi Jami, Undergraduate Student, Capstone Scholar, Project Advisor and Trainer, Case Western Reserve University
2014	Lisa Liang, Undergraduate Student, Capstone Scholar, Project Advisor and Trainer, Case Western Reserve University
2014	Raj Nanavaty, Undergraduate Student, Ohio State University, Project Advisor and Trainer, Ohio State University
2015-2016	Mario Candamo, Undergraduate Student, Capstone Scholar, Project Advisor and Trainer, Case Western Reserve University
2015-2016	Albert Lee, Undergraduate Student, Capstone Scholar, Project Advisor and Trainer, Case Western Reserve University
2015-2016	Jeniece Montellano, Undergraduate Student, Capstone Scholar, Project Advisor and Trainer, Case Western Reserve University

2015-2017	Shardul Soni, Pathology Graduate Student, Project Advisor and Trainer, Case Western Reserve University
2016-2017	Michael Glover, Medical Student, Project Advisor, Case Western Reserve University
2016-2017	Aditya Joshi, Capstone Project Advisor and Trainer, Case Western Reserve University
2016-2017	Aditi Goel, Undergraduate Student, Project Advisor and Trainer, Case Western Reserve University
2016-2018	Victoria El-Hayek, Undergraduate Student, Project Advisor and Trainer, Case Western Reserve University
2016-2018	Daniel Franco, Undergraduate Student, Project Advisor and Trainer, Case Western Reserve University
2016-2017	Muhammad Ali, Medical Student, Project Advisor and Trainer, Dow Medical College, Pakistan
2017-2019	Omair Iqbal, Undergraduate Student, Project Advisor and Trainer, Case Western Reserve University
2017-2019	Nathan Sundheimer, Project Advisor and Trainer, Weatherhead School of Management, Case Western Reserve University
2017-2018	Charvi Malhotra, Capstone Project Advisor and Trainer, Case Western Reserve University
2018-2019	Spencer Lin, Project Advisor and Trainer, Case Western Reserve University

High School/Undergraduate Students:

2004	Andrew Keller, High school student, Project Advisor, Case Western Reserve University
2005	Harold Wu, High School Student, Project Advisor, Case Western Reserve University
2006	Ramneek Bedi, High School Student, Project Advisor, Case Western Reserve University
2008	Chanelle Williams, High School Student, Project Advisor, Case Western Reserve University
2009	Josea Switzer, High School Student, Project Advisor, Case Western Reserve University
2010-2011	Nneka Adigwe, High School Student, Project Advisor, Case Western Reserve University
2012-2013	Tavaris Tucker, High School Student, Project Advisor, Case Western Reserve University
2016	Tarini Singh, Berea-Midpark High School Student (Scientific Enrichment and Opportunity Program), Project Advisor
2018	Amrita Siri Mukunda, Hawken High School Student, Project Advisor, Case Western Reserve University
2018	Che Jarvis, High School Student (Scientific Enrichment and Opportunity Program) Project Advisor

Post-doctoral Trainee in Faculty Positions:

<u>Post-doctoral fellow</u>	<u>Faculty Position</u>
Sanjeev Shukla, Ph.D.	Assistant Professor, Case Western Reserve University, Cleveland, OH
Farrukh Afaq, Ph.D.	Assistant Professor, University of Alabama at Birmingham, AL
Vaqar M Adhami, Ph.D.	Associate Scientist, University of Wisconsin, Madison, WI
Janmejai K Srivastava, Ph.D.	Professor, Amity University, Lucknow, India
Ata Abbas, Ph.D.	Adjunct Assistant Professor, Cleveland Clinic Foundation, Cleveland, OH

TEACHING ASSIGNMENTS

Fall 2007	Preceptor, Case Inquiry Group, Block 2, The Human Blueprint, Case Medical School, September/October, 2007
Spring 2007	Prostate Cancer Chemoprevention: Clinical Trials with Green Tea Polyphenols, CME Lecture presented at Innovations in Urologic Oncology, March 9-10, 2007 at Wolstein Research Building, University Hospitals Case Medical Center
Spring 2008	Lecture on 'Epidemiology of Prostate Cancer' Epidemiology and Biostatistics Course, Module 3, Male Reproductive Health, April, 2008
2008	Cyclooxygenase-2 and 5-Alpha Reductase Enzymes in Prostate Cancer: Is There Any Link? CME Lecture at 136 th Advanced Course on Steroid Enzymes and Cancer, May 3-8, 2008 at Erice, Italy

Spring 2009	Lecture on 'Cancer Chemoprevention' in course on Basic Cancer Biology and the Interface with Clinical Oncology: PHRM 520 (PATH 520)
Fall 2009	Preceptor, Case Inquiry Group, Block 2, The Human Blueprint, Case Medical School, September/October, 2009
Spring 2011	Lecture on 'Concepts of Cancer Chemoprevention' in course on Basic Cancer Biology and the Interface with Clinical Oncology: PHRM 520 (PATH 520)
Spring 2013	Lecture on 'Cancer Chemoprevention-Basic Concepts' in course on Basic Cancer Biology and its interface with Clinical Oncology –Master's degree program (PHRM 520/PATH 520)
Spring 2014	Lecture on 'Cancer Chemoprevention-An Introduction' in course on Basic Cancer Biology and its interface with Clinical Oncology –Master's degree program (PHRM 520/PATH 520)
Spring 2015	Lecture on 'Introduction to Cancer Chemoprevention' in course on Basic Cancer Biology and its interface with Clinical Oncology –Master's degree program (PHRM 520/PATH 520)
Spring 2016	Lecture on 'Cancer Chemoprevention' in course on Basic Cancer Biology and its interface with Clinical Oncology –Master's degree program (PHRM 520/PATH 520)
Spring 2017	Lecture on 'Cancer Chemoprevention: An Introduction' in course on Basic Cancer Biology and its interface with Clinical Oncology –Master's degree program (PHRM 520/PATH 520)
Spring 2019	Lecture on 'Cancer Chemoprevention: Current Concepts' in course on Basic Cancer Biology and its interface with Clinical Oncology –Master's degree program (PHRM 520/PATH 520)

MAJOR LECTURES

Presentations at International, National, Regional and In-house Meetings:

05/2001	Apigenin: A Novel Agent for Prostate Cancer Chemoprevention, Prostate Group at Case Western Reserve University, May 23, 2001
10/2002	Green Tea and Prostate Cancer, University Hospitals of Cleveland, Urology Residents, October 12, 2002
05/2003	Suppression of Prostate Carcinogenesis in TRAMP Mice by Dietary Supplementation of <i>Celecoxib</i> : A Selective COX-2 Inhibitor, Bioluminescence Meeting at Biomedical Engineering Building, Case Western Reserve University, May 28, 2003
11/2003	Is Transcription Factor NF- κ B a Molecular Target for Prostate Cancer, University Hospitals of Cleveland, Urology Residents, November 15, 2003
11/2004	PI3K-Akt and NF- κ B Signaling During Prostate Cancer Progression, University Hospitals of Cleveland, Urology Residents, November 13, 2004
02/2005	Green Tea and Prostate Cancer: An Update, Prostate Cancer Education/Discussion Group in the Good Company to prostate cancer survivors, families and friends at Lerner Tower, University Hospitals/Ireland Cancer Center, February 24, 2005
04/2005	PI3K-Akt and NF- κ B Signaling Pathways in Prostate Cancer, The Prostate Group Meeting, University Hospitals of Cleveland, April 8, 2005
01/2006	Role of PI3K-Akt and NF- κ B During Prostate Cancer Progression presentation to faculty and graduate students at the Department of Electrical Engineering & Computer Sciences, Division of Case System Biology, Case Western Reserve University, January 24, 2006
04/2006	Prostate Cancer Progression in TRAMP Mice presentation to the faculty, postdoctoral fellows and graduate students at the Department of Biophysics and Physiology, Case Western Reserve University, School of Medicine, April 18, 2006
04/2006	Influence of Chronic Inflammation on Prostate Carcinogenesis: A Five Year Follow-up Study at 97 th Annual Meeting of American Association for Cancer Research, April 2, 2006

08/2006 Epigenetics and Cancer Chemoprevention: Promise, Prospects and Challenges at International Conference on Frontiers of Pharmacology and Toxicology, Chicago, August 28-31, 2006

12/2006 Apigenin and Prostate Cancer: Progress and Promise presentation to the faculty, postdoctoral fellows and graduate students at the Department of Nutrition, Case Western Reserve University, School of Medicine, December 1, 2006

03/2007 Role of Green Tea Polyphenols in Epigenetics and Cancer Prevention presentation to the faculty, postdoctoral fellows at the Department of Hematology/Oncology, Cleveland Clinic Foundation, March 27, 2007

04/2007 Apigenin-induced Prostate Cancer cell Death is Initiated by Reactive Oxygen Species and p53 Activation at 99th Annual Meeting of American Association for Cancer Research, April 15, 2007

07/2007 Green Tea in Epigenetic Regulation: A Novel Path to Cancer Chemoprevention at the Case Comprehensive Cancer Center Retreat, July 13, 2007

10/2008 Connecting PI3K-Akt-NF- κ B Pathway in Prostate Cancer through Systems Biology Systems Biology Group Meeting at Wolstein Building, October 31, 2008

09/2009 Inflammation and Prostate Cancer: Is There a Link? MetroHealth Medical Center, Rammelkamp Center for Education & Research, September 15, 2009

01/2010 An Introduction to Cancer Chemoprevention, seminar to graduate students and faculty members at the Cleveland State University, January 29, 2010

12/2010 Effect of High-fat Diet on Prostate Remodeling, CWRU Interdisciplinary Research Center for Urological Complications of Obesity and Diabetes (UCOD), at the George S Dively Building, Case Western Reserve University, Cleveland, Ohio December 08, 2010

05/2011 Translational Urology Research; Step-by-step, How to Do it: From Concepts to Getting Funded at the American Urological Association 2011 Annual Meeting in Washington DC, May 17, 2011

08/2011 Inflammation and Prostate Cancer: An Update, seminar to graduate students, residents and faculty members, Department of Urology, Case Western Reserve University, August 1, 2011

09/2011 Epigenetics and Cancer Prevention: Role of Green Tea Polyphenols, to graduate students and faculty members in the Department of Pharmacology, Case Western Reserve University, September 20, 2011

09/2011 Effect of High-Fat Diet on Prostate Remodeling, presentation at the National Urology Research Preceptorship Program at Case Western Reserve University, September 29, 2011

12/2012 Effect of Lyc-O-Mato® on Bladder Tumor Recurrence, Translational Cancer Center Meeting, Ruhlman Conference Center, December 09, 2011

12/2012 Effect of Polyphenon E in Active Surveillance Patients, Translational Cancer Center Meeting, Ruhlman Conference Center, December 09, 2011

02/2012 Diet, Obesity and Chronic Inflammation: Role in Prostatic Diseases, presentation at Nutrition Obesity Research Center, Case Western Reserve University, Cleveland, Ohio, February 06, 2012

04/2012 Dietary Factors Promoting Intraprostatic Inflammation BPH/LUTS, Senior Investigator's Meeting for O'Brien Center Grant in Benign Urology, Urology Department, April 16, 2012

06/2012 Role of Special AT-Rich Binding Protein (SATB1) in Prostate Cancer Progression, Presentation at the Prostate Group Meeting, Wolstein Cancer Center, June 21, 2012

07/2012 Dietary Factors Promoting Enlarged and Inflamed Prostate presentation at the National Urology Research Preceptorship Program at Case Western Reserve University, July 16-17, 2012

05/2014 Simvastatin and Metformin: A Deadly Combination for Metastatic Castration-Resistant Prostate Cancer, Annual Meeting of the American Urological Association, Orlando, Florida, May 20, 2014

- 06/2014 Molecular insights into the epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) by green tea polyphenols in breast cancer cells. Annual Meeting of the Indian Association for Cancer Research (IACR), Kerala, India June 18-20, 2014
- 01/2015 Chemoprevention of Prostate Cancer by Naturally Occurring Compounds, Presentation for Parker Moss Professorship in Integrative Oncology, Wolstein Research Building WRB 5-136, January 19, 2015

INVITED LECTURES & VISITING PROFESSORSHIP

- 03/2005 Evaluating the Chemopreventive Efficacy of Apigenin in Prostate Cancer, Invited Guest Speaker at International Symposium on Diet in Causation and Prevention of Cancer, Industrial Toxicology Research Center, Lucknow, India March 17-19, 2005
- 10/2005 The Promise of Cancer Chemoprevention: Plant Flavonoid Apigenin in Prevention of Prostate Cancer, Invited Speaker in the Department of Nutrition, Purdue University, Indiana, October 14, 2005,
- 12/2005 Biomarker Studies in Prostate Cancer, Invited Guest Speaker at the Prostate Cancer Biomarkers Conference at the Inverness Hotel and Conference Center, sponsored by the University of Colorado Cancer Center and Department of Medicine, December 9-10, 2005
- 05/2006 Does chronic inflammation influences prostate carcinogenesis? A five year follow-up study, Invited Discussion Panel in the Annual Meeting of American Urological Association, 2006
- 07/2006 Prostate Cancer Chemoprevention by Apigenin: A Tale of Promise, Invited Guest Speaker, Distinguished Visitor Seminar Series, Markey Cancer Center, University of Kentucky, Lexington, July 27, 2006
- 08/2006 Epigenetics and Cancer Chemoprevention: Promise, Prospects and Challenges at International Conference on Frontiers of Pharmacology and Toxicology, Chicago, August 28-31, 2006
- 03/2007 Prostate Cancer Chemoprevention by Plant Flavonoid Apigenin: Scientific Promise and Clinical Utility, Distinguished Seminar Series, Henry Ford Health System, Detroit, MI, March 1, 2007
- 07/2007 Apigenin and Prostate Cancer Chemoprevention: Recent Developments, Invited Guest Speaker, Department of Pharmaceutical Sciences, University of Colorado Health Science Center, Colorado, July 25, 2007
- 08/2007 Green Tea and Prostate Cancer Prevention: A New Role in Regulating Epigenetic Mechanisms, Invited Guest Speaker, Cancer Prevention & Control Program, Brown Cancer Center, University of Louisville, Kentucky, August 28, 2007
- 09/2007 Remodeling of Epigenome by Green Tea Polyphenols: Implication for Prostate Cancer Chemoprevention, Invited Guest Speaker at the Hormel Institute, Austin, Minnesota, September 14, 2007
- 02/2008 Green Tea and Prostate Cancer: A Journey of its Development as Chemopreventive Agent, Speaker at Indiana University Cancer Center, Indianapolis, February 27, 2008
- 03/2008 Deregulation of the Forkhead Transcription Factor Class 'O' Proteins During Prostate Cancer Progression, Invited Guest Speaker at the 4th Annual National Symposium on Prostate Cancer, Clark Atlanta University, Atlanta, Georgia, March 18, 2008
- 04/2008 Epigenome and Prostate Cancer: New Possibilities of Cancer Prevention with Green Tea Polyphenols, Speaker at Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, April 22, 2008
- 07/2008 Forkhead Transcription Factor Class "O" Dysregulation during Prostate Cancer Progression, Era Medical College, Lucknow, India, August 5, 2008
- 07/2008 Inflammation and Prostate Cancer: Is There a Link? Invited Speaker at the King George's Medical University, Lucknow, India, August 6, 2008

- 07/2008 Role of Inflammation in the Development of Prostate Cancer, Jawaharlal Nehru University, New Delhi, India, August 12, 2008
- 10/2008 Maspin: A Novel Target for Suppression of Prostate Cancer Progression by Apigenin, Speaker at the 13th World Congress on Advances in Oncology & 11th International Symposium on Molecular medicine, Creta Maris, Heronissos, Crete, Greece, October 11, 2008
- 12/2008 Epigenetics and Cancer Prevention: Role of Dietary Polyphenols, Invited Speaker at the International Symposium on "Novel Strategies for Targeted Prevention and Treatment of Cancer" Jawaharlal Nehru University, New Delhi, India December 19, 2008
- 03/2009 TRAMP and Prostate Cancer Progression: "Hands on Training" Invited to provide training to the researchers at the Henry Ford Hospital, Detroit, MI, March 12, 2009
- 04/2009 Chemopreventive and Therapeutic Efficacy of Plant Flavone Apigenin against Prostate Cancer, Invited Speaker at the Department Seminar Program, Department of Chemistry & Biochemistry, Miami University, Oxford, Ohio April 9, 2009
- 05/2009 Epigenetic Reprogramming by Plant Polyphenols: Implications for Cancer Prevention, Invited Speaker in the Department of Molecular Biology & Immunology at the University of North Texas Health Science Center at Fort Worth, Texas May 6, 2009
- 11/2009 NF- κ B: A Molecule of Diagnostic and Therapeutic Value in Prostate Cancer, Invited Speaker at the 2009 SBUR/ESUR Joint Meeting and the 8th World Basic Urological Research Congress, Sheraton New Orleans, New Orleans, Louisiana, November 7, 2009
- 06/2010 Diet, Epigenetics and Cancer Prevention, Distinguished Lecture hosted by Department of Medicine and Mason Eye Institute, University of Missouri-Columbia, June 23, 2010
- 12/2010 Nuclear Factor- κ B: A Diagnostic and Therapeutic Target in Prostate Cancer, Invited Presentation at the International Cancer Research Symposium 2010: Defining & Translating Science for Disease Prevention & Treatment, Rajiv Gandhi Center for Biotechnology, Thiruvanthapuram, India, December 21, 2010
- 03/2011 Epigenetics and Cancer Prevention: Researching A New Paradigm, Invited Speaker at the seminar talk to the Graduate Students and Faculty, Department of Biology, Georgia State University, March 18, 2011
- 08/2011 Linking Inflammation with Prostate Cancer: A New Player in the Game, Invited Speaker at the Prostate and Prostate Cancer Research Group Meeting, University of Wisconsin, Madison, Wisconsin, August 5, 2011
- 10/2011 Epigenetic Reprogramming by Plant Polyphenols: Implications for Cancer Prevention, Invited Speaker at the New York University School of Medicine, Nelson Institute of Environmental Medicine, Tuxedo, New York, October 7, 2011
- 11/2011 From Men to Mice: Evidence Basis for Integrative Medicine Practices in Cancer Prevention & Care, Invited Speaker at the Eighth International Conference of the Society for Integrative Oncology, InterContinental Hotel, Cleveland Clinic, November 10-12, 2011
- 12/2011 Urologic Complications of Obesity and Diabetes, data presentation at the Urology Program Director's Meeting, Turf Valley Hotel, Ellicott City, Maryland, November 30-December 2, 2011
- 12/2011 Diet, Obesity and Chronic Inflammation: Role in Urologic Complications, Invited Speaker AT THE 22ND All India Congress of Zoology & National Seminar on Recent Advances in Biological Sciences: Biodiversity and Human Welfare, University of Lucknow, India 29-31 December, 2011
- 05/2012 Development of Diet-derived Agents in the Prevention and Therapy of Prostate Cancer, Invited Speaker at the Georgia Health Sciences University Cancer Center, Augusta, Georgia May 15, 2012
- 10/2012 Epigenetic Regulation by Green Tea Polyphenols, Invited Speaker at the 2012 CPMDRC International Symposium at the Kyung Hee University, South Korea October 12, 2012

- 12/2012 Plant Flavonoids as Epigenetic Modulators in Cancer: Implications in Cancer Chemoprevention, Invited Speaker at the 3rd International Cancer Research Symposium 2012—Defining & Translating Science for Disease Prevention & Therapy at the Swissotel, Kolkata, India December 18-21, 2012
- 03/2014 Green Tea Polyphenols as Epigenetic Modifiers: Role in Tumor Metastasis, Invited Speaker at the 2014 Cancer Prevention and Chemoprevention Symposium: State of the Art, UAB Comprehensive Cancer Center, Alabama, March 27, 2014
- 10/2014 Modification of the Epigenome by Green Tea Polyphenols: Role in Cancer Prevention, 4th World Congress on Cancer Science & Therapy, Chicago, IL October 20-22, 2014
- 10/2015 Symposium on Latest Treatments and Emerging Therapies in Cancer at the Cancer Middle East, Dubai, UAE, October 05, 2015
- 10/2015 A Paradigm Shift: Combinatorial chemotherapy with simvastatin and metformin for castrate-resistant prostate cancer. 6th Global Summit on Cancer, Omics Group, Dubai October 5-7, 2015
- 04/2016 Biomarker Discovery and Translational Chemoprevention Studies in Prostate Cancer: A Decade of Research, Seminar Speaker, Purdue University, Center for Cancer Research, March 24, 2016
- 12/2016 Targeting Cancer Cell Metabolism by Repurposing Clinically Approved Drugs at the 5th International Conference on Pharmaceutical Sciences, Dubai, UAE December 7-8, 2016
- 02/2017 Targeting Cellular Bioenergetics in Cancer Cells by Repurposing Clinically Approved Drugs, International Conference on “Mitochondria in Health and Disease” of Society for Mitochondrial Research and Medicine-India (SMRM) at JNU, New Delhi, India February 10-11, 2017
- 10/2017 Dietary polyphenols as epigenetic modulators: Progress and challenges. 2nd International Conference on Cancer Research and Targeted Therapy, Miami Beach Resort, FL Oct 26-28, 2017
- 09/2018 Epigenetics and Cancer Prevention: Role of Polyphenols. 3rd International Conference on Nutraceuticals and Chronic Diseases (INCD) under the aegis of International Society of Nutraceuticals and Chronic Diseases, Swami Rama Himalayan University, Jolly Grant, Dehradun, India on September 14-16, 2018

EDITORIAL BOARD MEMBERSHIP

Current

- 2012-present **Cancer Letters: Editorial Board Member**, an international journal publishes in the broad area of basic and translational oncology. Topics in Cancer Letters include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal places emphasis on experimental therapeutics, particularly targeted therapies for personalized cancer medicine.
Web-site: <https://www.journals.elsevier.com/cancer-letters/editorial-board>
ISSN: 0304-3835
- 2013-present **Discoveries Journals: Senior Editor**, Discoveries and Discoveries Reports are peer reviewed, open access, online multidisciplinary and integrative journals publishing high impact and innovative reviews, experimental articles, perspective articles and editorials from all areas related to medicine, biology and chemistry, including but not limited to: Molecular and Cellular Biology, Biochemistry, Biophysics, Biotechnology, Synthetic Biology, Systems Biology, Bioinformatics, Translational Medicine, Medicine/Clinical findings, Epidemiology, Global Medicine, Family Medicine, Organic/Inorganic/Physical Chemistry and Ethics in Science.
Web-site: <https://discoveriesjournals.org/editorial-board>
ISSN: 2359-7232

- 2017-present **American Journal of Clinical and Experimental Urology: Senior Editor**, An Official Journal of Society of Basic Urology Research (SBUR), an open access, online journal to facilitate rapid publication and circulation of novel discoveries in basic, translational, and clinical studies of Urology. It was founded by a group of scientists in the relevant fields and clinical academic physicians from around the world, who are devoted to the advancement of understanding of this group of important diseases and the development of the therapies.
Web-site: <http://www.ajceu.us/editorialboard.html>
ISSN: 2330-1910
- 2014-present **International Journal of Advanced Nutritional and Health Science (IJANHS): Editorial Board Member**, a peer-reviewed, open access online journal which welcomes original research articles as well as review articles in all areas of nutritional & health science.
Web-site: <http://medical.cloud-journals.com/index.php/IJANHS/about/editorialTeam>
ISSN: 2348-5140
- 2012-present **Journal of Nutritional Disorders & Therapy: Editorial Board Member**, an Open Access, peer reviewed, academic journal and aims to publish most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide.
Web-site: <https://www.omicsonline.org/editorialboard-nutritional-disorders-therapy-open-access.php>
ISSN: 2161-0509
- 2010-present **World Journal of Clinical Oncology: Editorial Board Member**, a monthly peer-reviewed, online, open-access journal supported by an editorial board consisting of 310 experts in oncology from 33 countries. This journal aims to provide clinicians and researchers the most updated development and advancement and the major influential research results in clinical oncology.
Web-site: <https://www.wjgnet.com/2218-4333/EBoardMembers?pageNumber=2>
ISSN: 2218-4333
- 2009-present **Molecular Medicine Reports: Editorial Board Member**, a peer-reviewed journal understanding the cancer problem.
Web-site: <https://www.spandidos-publications.com/pages/mmr/editorial>
ISSN: 1791-3004
- 2007-present **Clinical Medicine: Urology: Editorial Board Member**, an open access, peer reviewed journal which considers manuscripts on all aspects of the diagnosis, management and prevention of urology disorders, in addition to related genetic, patho-physiological and epidemiological topics.
Web-site: <https://us.sagepub.com/en-us/nam/clinical-medicine-insights-urology/journal202646#editorial-board>
ISSN: 1178-2188
- 2015-present **Oncology Discovery: Editorial Board Member**, an Open Access (Gold OA), peer reviewed, international online publishing journal, which aims to publish premier papers on all the related areas of advanced research carried on in the field of oncology and its interdisciplinary branches.
Web-site: <http://www.hoajonline.com/oncology/editorialboard>
ISSN 2052-6199
- 2015-present **World Journal of Clinical Urology: Editorial Board Member**, a high-quality, peer reviewed, open-access journal. The primary task of WJCU is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of urology. In order to promote productive academic communication, the peer review process for the WJCU is transparent; to

this end, all published manuscripts are accompanied by the anonymized reviewers' comments as well as the authors' responses. The primary aims of the WJCU are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in urology.

Web-site: <https://www.wjgnet.com/2219-2816/EBoardMembers?pageNumber=2>

ISSN: 2219-2816

- 2015-present **Andrology-Open Access: Editorial Board Member**, publishes the most exciting researches related to Andrology: Second to provide a rapid turn-around time possible for reviewing and publishing of articles freely for research, teaching and reference purposes.
Web-site: <https://www.omicsonline.org/editorialboard-andrology-open-access.php>
ISSN: 2167-0250
- 2015-present **Journal of Food and Nutrition (JFN): Editorial Board Member**, an open access journal, that publishes articles covering fundamental and applied research in all disciplines of food and nutrition mainly focusing on Nutrition and Food Science, Nutritional Disorders, Vitamin & mineral nutrition- Current research, Carbohydrate and protein nutrition, Pediatric Nutrition, Food Preservation and Quality Control, Food Technology Applications, Agriculture Biotechnology, Food Processing Industries, Nutrigenomics and nutrigenomics, Organic nutrition, Applications of nanotechnology in food and nutrition.
Web-site: <http://www.jscholaronline.org/journals/journal-of-food-and-nutrition/editorial-board.php>
ISSN: 2375-6829
- 2015-present **Journal of Urology & Nephrology: Editorial Board Member**, an international, Online Open Access, peer reviewed journal that provides current information of research, development and treatment aspects that are involved in the fields of urology and nephrology.
Web-site: <http://www.avensonline.org/medical/journal-of-urology-nephrology/editorial-board-37/>
ISSN: 2380-0585
- 2015-present **SM Journal of Nutrition and Metabolism (SMJNM): Editorial Board Member**, an International Peer Reviewed Open Access journal presenting original research contributions and scientific advances in the field of Nutrition and Metabolism. Covering broad research areas, SMJNM aims to promote information in Clinical Nutrition and related sciences and enhance exchange of scientific literature among peers. It also serves as a platform to promote meetings and news relating to advances in Nutrition and Metabolism.
Web-site: <http://smjournals.com/nutrition-metabolism/editorial-board.php>
ISSN: 2573-5462
- 2015-present **Journal of Urology and Nephrology Open Access: Editorial Board Member**, an international, open access, peer-reviewed, scientific journal for showcasing modern research in Urology and Nephrology.
Web-site: <https://symbiosisonlinepublishing.com/urology-nephrology/editorialboard.php>
ISSN: 2473-6430
- 2015-present: **SM Journal of Urology (SMJU): Editorial Board Member**, an International Peer Reviewed Open Access journal presenting original research contributions and scientific advances in the field of Urology. Covering broad research areas, SM Journal of Urology aims to promote information in Urology and related sciences and enhance exchange of scientific literature among peers. It also serves as a platform to promote meetings and news relating to advances in Urology.
Web-site: <http://smjournals.com/urology/editorial-board.php>
ISSN: 2574-8017
- 2016-present **Austin Andrology: Editorial Board Member**, an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Andrology.

Web-site: <http://austinpublishinggroup.com/andrology/editorialBoard.php>

- 2016-present **Austin Food Sciences: Editorial Board Member**, an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Food Sciences.
Web-site: <http://austinpublishinggroup.com/food-sciences/editorialBoard.php>
- 2016-present **Reactive Oxygen Species (ROS): Editorial Board Member**, a peer-reviewed journal dedicated to the rapid dissemination of new knowledge on reactive oxygen and related species/entities (including antioxidants) in chemistry, biology, and medicine.
Web-site: <https://www.aimsoci.com/ros/index.php/ros/about/editorialTeam>
- 2017-present **Scholarena Journal of Food and Nutrition (SAJNF): Eminent Editorial Board Member**, a peer reviewed, open access journal which covers wide aspects in the field of nutrition and food. SAJNF provides an extensive information for researchers and academicians.
Web-site: <http://www.scholarenajournals.com/journals/saj-food-and-nutrition/jhome.php>
- 2017-present **Elyns Journal of Urology: Editorial Board Member**, an international online open access peer reviewed journal which acts as a forum for clinical practitioners and researchers to provide complete, reliable source of information in field of urology.
Web-site: <https://www.elynsgroup.com/journal/editorial-board/elyns-journal-of-urology>
- 2018-present **International Journal of Carcinogenesis and Mutagenesis: Editorial Board Member**, an online open access scientific journal which publishes quality articles from all the subjects where normal cells are transformed into cancer cells and genetic information of an organism is changed, resulting in a mutation also serves as a platform to promote meetings and news relating to advances in carcinogenesis and mutagenesis.
Web-site: https://gavinpublishers.com/journals/board_members/International-Journal-of-Carcinogenesis-and-Mutagenesis
- 2018-present **Annals of Urologic Oncology (AUO)--Asian Medical Press: Assistant Editor**, an online journal that publishes the results of novel research in the laboratory and clinical settings, including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human urologic oncology with the overall goal of improving clinical care of patients with urologic tumors.
Web-site: <http://www.asmeppress.com/Editorial-board.html>
Print ISSN: 2617-7765, Online ISSN: 2617-7773

Past

- 2013-2016 **Journal of Nutrition Research: Editor-in-Chief**, an open access journal publishes research articles, communications, and reviews on all aspects of basic and applied nutrition. It presents up-to-date, concise, critical reviews of key topics in nutrition science advancing new concepts and hypotheses that encourage the exchange of fundamental ideas on nutritional well-being in both humans and animals.
- 2014-2016 **American Journal of Pharmaceutical Sciences (AJPS): Editorial Board Member**, an international scientific eJournal that publishes all areas of pharmaceutical sciences, pharmaceuticals, pharmacognosy, pharmaceutical analysis, organic, synthetic and medicinal chemistry. It broadly accepts all the areas of chemistry, i.e. isolation, activity of chemicals, synthesis.
- 2012-2016 **Journal of Medical & Surgical Urology: Editorial Board Member**, focuses on the research prospectus of urinary tracts and reproductive system of both males and females. Medical & Surgical Urology Journal encompasses the biological, surgical, clinical & medical aspects on uro-oncology, renal transplants, reconstructive urology, renal physiology, calculi etc. The journal

is aimed at providing readership with current research topics and comprehensive reviews on all aspects of medical & surgical urology.

- 2010-2016 **Chinese Journal of Clinicians: Editorial Board Member**, an open accessed, peer reviewed scholarly journal publishes original research articles, technical advances and study protocols in areas of medical science or clinical practice.
- 2009-2017 **The Open Biomarkers Journal: Editorial Board Member**, an open Access online journal, which publishes original full-length, short research articles and reviews on biomarkers in clinical, medical and pharmaceutical research. The coverage includes biomarkers of disease, new biomarkers, exposure to drugs, genetic effects, and applications of biomarkers.
- 2008-2017 **The Open Bioactive Compounds Journal: Editorial Board Member**, a peer-reviewed journal, aims to provide the most complete and reliable source of information on current developments and research in new bioactive compounds with proven activities in various biological screenings and pharmacological models.
- 2007-2017 **The Open Biochemistry Journal: Editorial Board Member**, a peer reviewed journal, aims to provide the most complete and reliable source of information on disease processes; pharmacology; biochemistry; molecular biology; genetics; chemistry; cell biology; neuroscience; immunology; pathology.
- 2009-2017 **Medical & Surgical Urology: Editorial Board Member**, an open access publication that features scientific works of considerable importance in all fields of Urology.

ADHOC REVIEWER IN OTHER SCIENTIFIC JOURNALS

- | | |
|--------------|---|
| 2013-present | AAPS Journal |
| 2013-present | American Journal of the Medical Sciences |
| 2015-present | American Journal of Nephrology |
| 2009-present | Antioxidant & Redox Signaling |
| 2006-present | Asian Journal of Andrology |
| 2016-present | Asian Journal of Urology |
| 2013-present | BBA-Molecular Basis of Disease |
| 2015-present | Biomedical and Environmental Sciences |
| 2007-present | BMC Cancer |
| 2012-present | BMC Complementary & Alternative Medicine |
| 2006-present | British Journal of Cancer |
| 2005-present | Cancer Research |
| 2006-present | Carcinogenesis |
| 2009-present | Cancer Biology & Therapy |
| 2004-present | Cancer Letters |
| 2018-present | Cancer Research Frontiers |
| 2006-present | Cancer Epidemiology Biomarkers & Prevention |
| 2011-present | Cell Death & Disease |
| 2013-present | Cellular & Molecular Biology Letters |
| 2005-present | Clinical Cancer Research |
| 2006-present | Cancer Chemotherapy and Pharmacology |
| 2007-present | Current Drug Targets |
| 2012-present | Current Medicinal Chemistry |
| 2018-present | Current Pharmacology Reports |
| 2016-present | DNA and Cell Biology |
| 2013-present | Experimental Biology & Medicine |
| 2008-present | Expert Reviews in Molecular Medicine |
| 2012-present | Experimental & Molecular Pathology |
| 2018-present | Experimental and Therapeutic Medicine |

2012-present	Evidence-based Complementary & Alternative Medicine
2017-present	European Journal of Pharmacology
2006-present	FASEB Journal
2008-present	Food & Chemical Toxicology
2013-present	Frontiers in Epigenomics and Epigenetics
2008-present	Histology and Histopathology
2016-present	Histopathology
2007-present	Immunopharmacology and Immunotoxicology
2005-present	International Journal of Cancer
2006-present	Journal of Biological Chemistry
2017-present	Journal of Cancer Science & Therapy
2007-present	Journal of Cellular Biochemistry
2006-	Journal of Cellular Physiology
2017-present	Journal of Functional Foods
2007-present	Journal of Molecular Histology
2007-present	Journal of Nutritional Biochemistry
2018-present	Journal of Pathology Clinical and Medical Research
2015-present	JoVE, Journal of Visualized Experiments
2005-present	Journal of Urology
2013-present	Journal of Translational Medicine
2007-present	Life Sciences
2005-present	Molecular Cancer Therapeutics
2006-present	Molecular Carcinogenesis
2016-present	Molecular Cell International
2007-present	Molecular and Cellular Biochemistry
2013-present	Molecular & Cellular Endocrinology
2016-present	Molecular Medicine Reports
2010-present	Molecular Nutrition & Food Research
2012-present	Molecular Sciences
2007-present	Molecular Therapy
2005-present	Neoplasia
2005-present	Nutrition and Cancer
2006-present	Oncogene
2-16-present	Oncology Letters
2012-present	Oncology Discovery
2008-present	Pathology-Research and Practice
2016-present	Pharmacological Research
2009-present	Pharmaceutical Research
2004-2006	Photochemistry and Photobiology
2013-present	Prostate Cancer & Prostatic Diseases
2010-present	PLOS <i>One</i>
2005-present	Radiation Research
2015-present	Scientific Reports
2001-present	Toxicology and Applied Pharmacology
2017-present	Translational Cancer Research
2017-present	Tumor and Microenvironment
2004-present	Urology
2010-present	World Journal of Urology

PATENTS/INVENTIONS

Sanjay Gupta, Preventive/Therapeutic Properties of Chamomile Extract against Various Human Cancer.
Awarded: 09/22/2006

Sanjay Gupta, Combination of nuclear NF- κ B/p65 localization and gland morphological features from surgical specimens for prediction of early biochemical recurrence in prostate cancer patients.

Submitted: 11/15/2017

Sanjay Gupta, Novel programmable Prodrugs for Prevention and Treatment of Bone Metastasis

Submitted: 11/21/2018

PEER REVIEWED PUBLICATIONS/REVIEWS

1. Srivastava RC, Srivastava SK, **Gupta S**, Athar M and Hasan SK: Evaluation of nickel complexes of bioligands- Effect on distribution profile. Res Comm Chem Pathol & Pharmacol 63:253-256, 1989 [PMID:2587843](#)
2. Behari JR, **Gupta S**, Srivastava S and Srivastava RC: Use of liposome encapsulated sodium 2, 3-dimercapto propane sulphonate (DMPS) in the treatment of mice loaded with cadmium. J Environ Sci Health A 25:597-610, 1990
3. Srivastava RC, Kumar A, Srivastava SK, **Gupta S**, Hasan SK and Athar M: Nickel-mediated inhibition in the glutathione-dependent protection against lipid peroxidation. Biochem Int. 20:495-501, 1990 [PMID:2346498](#)
4. **Gupta S**, Athar M, Behari JR and Srivastava RC: Cadmium-mediated induction of cellular defence mechanism: A novel example for the development of adaptive response against a toxicant. Ind Health. 29:1-9, 1991 [PMID:2026506](#)
5. Srivastava S, **Gupta S**, Behari JR and Srivastava RC: Mobilization of cadmium by liposome-encapsulated meso-2, 3-dimercaptosuccinic acid in pre-exposed mice. Toxicology Lett. 59:125-131, 1991 [PMID:1661448](#)
6. Behari JR, Srivastava S, **Gupta S** and Srivastava RC: Effect of liposome encapsulated meso 2, 3-dimercapto-succinic acid (DMSA) on biochemical and trace metal alterations in cadmium-exposed rats. Bull Environ Contam Toxicol. 47:827-833, 1991 [PMID:1686193](#)
7. Behari JR, **Gupta S**, Srivastava S and Srivastava RC: Modulation of liposomal lipid peroxidation in presence of nickel by incorporation of α -tocopherol in the bilayer. J Microencapsulation. 8:215-220, 1991 [PMID:1765901](#)
8. Behari JR, **Gupta S**, Srivastava S and Srivastava RC: Influence of size of liposomes in potentiating the efficacy of encapsulated triethylenetetramine-hexaacetic acid (TTHA) against cadmium intoxication. Ind Health. 31:29-33, 1993 [PMID:8340227](#)
9. Srivastava RC, Hasan SK, Jyotsana and **Gupta S**: Protective role of metallothionein in nickel induced oxidative damage. Biochem & Mol Biol Int. 30:261-270, 1993 [PMID:8364408](#)
10. **Gupta S**, Behari JR, Srivastava S, Misra M and Srivastava RC: Efficacy of liposome encapsulated triethylenetetraamine hexaacetic acid (TTHA) against cadmium intoxication: Role of lipid composition. Ind Health. 33:83-88, 1994 [PMID:7394825](#)
11. Husain MM, Ahmad N, **Gupta S**, Behari JR, Hasan SK, Srivastava SK and Srivastava RC: Exacerbation of nickel induced oxidative response by vitamin E. Ind Health. 33:143-152, 1995 [PMID:8543477](#)
12. Behari JR, Srivastava S, **Gupta S**, Misra M and Srivastava RC: Influence of 2, 3-dimercaptosuccinic acid esters administered via liposomes on biochemical alterations and cadmium levels in cadmium pre-exposed rats. Jour Sci Ind Res. 3:27-31, 1995
13. Srivastava RC, **Gupta S**, Ahmad N, Hasan SK, Farookh A and Husain MM: Comparative evaluation of chelating agents on the mobilization of cadmium: A mechanistic approach. J. Toxicol. & Environ. Health. 47:101-110, 1996 [PMID:8598573](#)
14. **Gupta S**, Ahmad N and Mukhtar H: Involvement of nitric oxide during phthalocyanine (Pc4)-photodynamic therapy mediated apoptosis. Cancer Res. 58:1785-1788, 1998 [PMID:9581812](#)

15. Mohan RR, Challa A, **Gupta S**, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, and Mukhtar H: Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin. Cancer Res. 5:143-147, 1999 [PMID:9918212](#)
16. Ahmad N, **Gupta S**, and Mukhtar H: Involvement of retinoblastoma (Rb) and E2F transcription factors during photodynamic therapy of human epidermoid carcinoma cells A431. Oncogene 18:1891-1896, 1999 [PMID:10086343](#)
17. **Gupta S**, Ahmad N, Mohan RR, Husain MM, and Mukhtar H: Prostate cancer chemoprevention by green tea: *In vivo* and *in vitro* inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res. 59:2115-2120, 1999 [PMID:10232597](#)
18. Haqqi TM, Anthony DD, **Gupta S**, Ahmad N, Lee M-S, Kumar GK, and Mukhtar H: Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc. Natl. Acad. Sci. USA 96:4524-4529, 1999 [PMID:10200295](#)
19. **Gupta S**, Ahmad N, and Mukhtar H: Prostate cancer chemoprevention by green tea. Seminars in Urologic Oncology 17:70-76, 1999 [PMID:10332919](#)
20. **Gupta S**, Srivastava M, Ahmad N, Bostwick DG and Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma The Prostate 42:73-78, 2000 [PMID:10579801](#)
21. **Gupta S**, Ahmad N, Nieminen A-L, and Mukhtar H: Growth inhibition, cell cycle dysregulation and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol. & App. Pharmacol. 164:82-90, 2000 [PMID:10739747](#)
22. Ahmad N, **Gupta S**, Husain MM, Heiskanen KM and Mukhtar H: Differential anti-proliferative and apoptotic response of sanguinarine for cancer cells Vs normal cells. Clin. Cancer Res. 6:1524-1528, 2000 [PMID:10778985](#)
23. Ahmad N, **Gupta S** and Mukhtar H: Green tea polyphenols epigallocatechin-3-gallate (EGCG) down-modulates the constitutive expression and activation of nuclear factor kappa B (NF- κ B). Arch. Biochem. Biophys. 376:338-346, 2000 [PMID:10775421](#)
24. **Gupta S**, Ahmad N, Husain MM and Srivastava RC: Involvement of nitric oxide in nickel-induced hyperglycemia in rats. Nitric Oxide: Biology and Chemistry 4:129-138, 2000 [PMID:10835293](#)
25. **Gupta S**, Ahmad N, MacLennan GT, Greenberg NM and Mukhtar H: Chemoprevention of prostate carcinogenesis by α -difluoromethylornithine in TRAMP mice. Cancer Res. 60:5125-33, 2000 [PMID:11016639](#)
26. Ahmad N, **Gupta S** and Mukhtar H: A role of Fas (APO-1/CD-95) in photodynamic therapy-induced apoptosis. J. Investigative Dermatol. 115:1041-1046, 2000 [PMID:11121139](#)
27. **Gupta S**, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG and Mukhtar H: Lipoygenase-5 is overexpressed in human prostate adenocarcinoma. Cancer 91:737-743, 2001 [PMID:11241241](#)
28. Srivastava M, Ahmad N, **Gupta S** and Mukhtar H: Involvement of Bcl-2 and Bax in photodynamic therapy mediated apoptosis: Antisense Bcl 2 oligonucleotide sensitizes RIF 1 cells to PDT-apoptosis. J. Biol. Chem. 276:15481-15488, 2001 [PMID:11278320](#)
29. **Gupta S**, Hastak K, Ahmad N, Lewin JS, and Mukhtar H: Prevention of prostate cancer in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci., USA 98:10350-10355, 2001 [PMID:11504910](#)
30. Berger SJ, **Gupta S**, Belfi CA, Gosky DM, and Mukhtar H: Green tea constituent (--)epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells. Biochem. Biophys. Research Communication 288: 101-105, 2001 [PMID:11594758](#)
31. **Gupta S**, Afaq F, and Mukhtar H: Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochemical Biophysical Res. Comm. 287: 914-920, 2001 [PMID:11573952](#)

32. **Gupta S** and Mukhtar H: Chemoprevention of skin cancer through natural agents. *Skin Pharmacology Applied Skin Physiology* 14:373-385, 2001 [PMID:11598437](#)
33. Ahmad N, Adhami VM, **Gupta S**, Cheng P, and Mukhtar H: Role of the retinoblastoma (pRb)-E2F/DP pathway in cancer chemopreventive effects of green tea polyphenol epigallocatechin-3-gallate. *Arch. Biochem. Biophys.* 398:125-131, 2002 [PMID:11811957](#)
34. **Gupta S**, Afaq F, and Mukhtar H: Involvement of Nuclear Factor-Kappa B, Bax and Bcl2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. *Oncogene* 21:3727-3738, 2002 [PMID:12032841](#)
35. **Gupta S** and Mukhtar H: Green tea and prostate cancer. *Urologic Clinics of North America* 29:49-57, 2002 [PMID:12109355](#)
36. **Gupta S** and Mukhtar H. Chemoprevention of skin cancer: current status and future prospects. *Cancer Metastasis* 21:363-80, 2002 [PMID:12549772](#)
37. **Gupta S**, Hussain T, MacLennan GT, Fu P, Patel J, and Mukhtar H: Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. *J. Clinical Oncol.* 21:106-112, 2003 [PMID:12506178](#)
38. **Gupta S**, Hussain T, and Mukhtar H: Molecular pathway for (-) epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. *Arch. Biochem. Biophys.* 410:177-185, 2003 [PMID:12559991](#)
39. Hastak K, **Gupta S**, Ahmad N, Agarwal MK, Agarwal ML, and Mukhtar H: Epigallocatechin-3-gallate-mediated induction of apoptosis in LNCaP cells is preceded by stabilization of p53 and modulation of NF- κ B leading to alteration in Bax/Bcl-2 ratio. *Oncogene* 22:4851-4859, 2003 [PMID:12894226](#)
40. Hussain T, **Gupta S**, Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. *Cancer Lett.* 191:125-135, 2003 [PMID:12618325](#)
41. **Gupta S**, Hastak K, Afaq F, Ahmad N, and Mukhtar H: Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. *Oncogene* 23:2507-2522, 2004 [PMID:14676829](#)
42. **Gupta S**, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, and Mukhtar H: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. *Cancer Res.* 64:3334-3343, 2004 [PMID:15126378](#)
43. Agarwal MK, Agarwal ML, Athar M, and **Gupta S**: Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. *Cell Cycle* 3:205-211, 2004 [PMID:14712090](#)
44. Shukla S and **Gupta S**: Molecular mechanisms for apigenin-induced cell cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. *Molecular Carcinogenesis* 39:114-126, 2004 [PMID:14750216](#)
45. Shukla S and **Gupta S**: Suppression of constitutive and TNF-alpha-induced NF- κ B activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: Correlation with down-regulation of NF- κ B responsive genes. *Clin. Cancer Res.* 10:3169-3178, 2004 [PMID:15131058](#)
46. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, and **Gupta S**: Nuclear Factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. *Neoplasia* 6:390-400, 2004 [PMID:15256061](#)
47. Hussain T, **Gupta S**, Adhami VM and Mukhtar H: Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. *Int. J. Cancer* 113:660-669, 2004 [PMID:15455372](#)
48. Adhami VM, Siddiqui IA, Ahmad N, **Gupta S** and Mukhtar H: Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. *Cancer Res.* 64:8715-8722, 2004 [PMID:15574782](#)

49. Shukla S, MacLennan GT, Marengo SR, Seftel AD, Resnick MI, and **Gupta S**: Genetic abnormalities in prostate cancer. *Current Genomics* 5:67-83, 2004
50. **Gupta S**: Prostate cancer chemoprevention: Models, limitations and potential. *Int. J Oncol.* 25:1133-1148, 2004 [PMID:15375566](#)
51. Saleem M, Adhami VM, Ahmad N, **Gupta S** and Mukhtar H: Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer development and chemoprevention regimens in an autochthonous mouse model. *Clin. Cancer Res.* 11:147-53, 2005 [PMID:15671539](#)
52. Shukla S, MacLennan GT, Marengo SR, Resnick MI and **Gupta S**: Constitutive activation of PI3K-Akt and NF- κ B during prostate cancer progression in autochthonous transgenic mouse model. *Prostate*, 64:224-39, 2005 [PMID:15712212](#)
53. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI and **Gupta S**: Upregulation of Insulin-like Growth Factor Binding Protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. *FASEB J.* 19:2042-4, 2005 [PMID:16230333](#)
54. Shukla S and **Gupta S**: Dietary agents in chemoprevention of prostate cancer. *Nutrition and Cancer*, 53:18-32, 2005 [PMID:16351503](#)
55. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, **Gupta S**: The influence of chronic inflammation in prostatic carcinogenesis: A five year follow-up study. *J Urol.* 176:1012-16, 2006 [PMID:16890681](#)
56. Shukla S and **Gupta S**: Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. *Mol Cancer Ther.* 5:843-52, 2006 [PMID:16648554](#)
57. **Gupta S**: Epigenetics and cancer chemoprevention: promise, prospects and challenges. *Chemico-Biol. Int.* 161(3): 213, 2006
58. Srivastava JK and **Gupta S**: Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. *Biochem. Biophys. Res. Comm.* 346:447-53, 2006 [PMID:16762318](#)
59. Hafeez BB, Ahmed S, Wang N, **Gupta S**, Zhang A, Haqqi TM: Green tea polyphenols-induced apoptosis in human osteosarcoma SAOS-2 cells involves a caspase-dependent mechanism with downregulation of Nuclear Factor-kappaB. *Toxicol Appl. Pharmacol.* 216:11-19, 2006 [PMID:16797629](#)
60. Shukla S and **Gupta S**: Apigenin-induced cell cycle arrest is mediated by modulation of MAPK and PI3K-Akt pathways, retinoblastoma dephosphorylation and loss of cyclin D1 in human prostate cancer cells. *Cell Cycle* 9:1102-1114, 2007 [PMID:17457054](#)
61. Shukla S, MacLennan GT, Hartman DJ, Fu P, Resnick MI and **Gupta S**: Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. *Int J Cancer* 121:1224-32, 2007 [PMID:17551921](#)
62. Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI and **Gupta S**: Blockade of Beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. *Cancer Res.* 67:6925-35, 2007 [PMID:17638904](#)
63. Srivastava JK and **Gupta S**: Anti-proliferative and apoptotic effects of chamomile extract in various human cancer cells. *J Agri & Food Chem.* 55:9470-9478, 2007 [PMID:17939735](#)
64. Patel DD, Shukla S and **Gupta S**: Apigenin and cancer chemoprevention. Progress, potential and promise *Int J Oncol.* 30:233-245, 2007 [PMID:17143534](#)
65. Vykhovanets EV, Resnick MI, MacLennan GT and **Gupta S**: Experimental rodent models of prostatitis: Limitations and potential. *Prostate Cancer & Prostatic Diseases* 10:15-29, 2007 [PMID:17199136](#)
66. **Gupta S**: Prostate cancer chemoprevention: Current status and future prospects. *Toxicol App Pharmacol.* 224:369-376, 2007 [PMID:17189645](#)

67. Vykhovanets EV, Shukla S, MacLennan GT, Resnick MI, Carlsen H, Blomhoff R, and **Gupta S**: Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1 β . *Prostate* 68:34-41, 2008 [PMID:18004768](#)
68. Shukla S and **Gupta S**: Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. *Free Rad Biol & Med.* 44:1833-45, 2008 [PMID:18342637](#)
69. Rabi T, Shukla S and **Gupta S**: Betulinic acid suppresses constitutive and TNF α -induced NF- κ B activation and induces apoptosis in human prostate carcinoma PC-3 cells. *Mol. Carcinog.* 47:964-973, 2008 [PMID:18444250](#)
70. Rabi T and **Gupta S**: Dietary terpenoids and prostate cancer prevention. *Front Biosci* 13:3457-69, 2008 [PMID:18508447](#)
71. Abbas A, **Gupta S**: The role of histone deacetylases in prostate cancer. *Epigenetics* 3:300-9, 2008 [PMID:19029799](#)
72. Zhou EH, Ellis RJ, Cherullo E, Colussi V, Xu F, Chen WD, **Gupta S**, Whalen CC, Bodner D, Resnick MI, Rimm AA, Koroukian SM. Radiotherapy and survival in prostate cancer patients: A population-based study. *Int J Radiat Oncol Biol Phys.* 73:15-23, 2009 [PMID:18538495](#)
73. Kaur P, Shukla S, **Gupta S**: Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: An in vitro and in vivo study. *Carcinogenesis* 29:2210-7, 2008 [PMID:18725386](#)
74. Shukla S, **Gupta S**: Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study. *Mol Carcinog* 48:243-52, 2009 [PMID:18726972](#)
75. Vykhovanets EV, Shukla S, MacLennan GT, Vykhovanets OV, Bodner DR, **Gupta S**: IL-1 β -induced post-transition effect of NF- κ B provides time-dependent wave of signals for initial phase of intrapostatic inflammation. *Prostate* 69:633-43, 2009 [PMID:19170127](#)
76. Shukla S, Shukla M, MacLennan GT, Fu P, **Gupta S**: Deregulation of FOXO3A during prostate cancer progression. *Int J Oncol.* 34:1613-20, 2009 [PMID:19424579](#)
77. Srivastava JK and **Gupta S**: Extraction, characterization, stability and biological activity of flavonoids isolated from chamomile flowers. *Mol & Cell Pharmacol.* 1:138-147, 2009 [PMID:20098626](#)
78. Srivastava JK, Pandey M, **Gupta S**: Chamomile, a novel and selective COX-2 inhibitor with anti-inflammatory activity. *Life Sci.* 85:663-9, 2009 [PMID:19788894](#)
79. Pandey M, **Gupta S**: Green tea and prostate cancer: From bench to clinic. *Front Biosci.* 1:13-25, 2009 [PMID:19482620](#)
80. Pandey M, Shukla S, **Gupta S**: Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. *Int. J Cancer*, 126:2520-33, 2010 [PMID:19856314](#)
81. Shukla S, **Gupta S**: Apigenin: a promising molecule for cancer prevention. *Pharm Res.* 27:962-78, 2010 [PMID:20306120](#)
82. Kanwal R, **Gupta S**: Epigenetics and Cancer. *J Appl Physiol.* 109:598-605, 2010 [PMID:20203073](#)
83. Bhaskaran N, Shukla S, Srivastava JK, **Gupta S**: Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity. *Int J Mol Med.* 26:935-40, 2010 [PMID:21042790](#)
84. Vykhovanets EV, Shankar E, Vykhovanets OV, Shukla S, **Gupta S**: High-fat diet increases NF- κ B signaling in the prostate of reporter mice. *Prostate*, 71:147-56, 2011 [PMID:20632379](#)
85. Nawab A, Yunus M, Mahdi AA, **Gupta S**: Evaluation of anticancer properties of medicinal plants from the Indian Sub-Continent. *Mol Cell Pharmacol.*, 3:21-29, 2011
86. Srivastava JK, Shankar E, **Gupta S**: Chamomile: A herbal medicine of the past with bright future. *Mol. Medicine Rep.*, 3:895-901, 2010 [PMID:21132119](#)

87. Vykhovanets EV, MacLennan GT, Vykhovanets OV, **Gupta S**: IL-17 expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. *Int J Clin Exp Pathol.* 4:552-65, 2011 [PMID: 21904631](#)
88. Thakur VS, Gupta K, **Gupta S**: The chemopreventive and chemotherapeutic potentials of tea polyphenols. *Current Pharm. Biotechnol.* 13:191-9, 2012 [PMID: 21466438](#)
89. Shankar E, Vykhovanets EV, Vykhovanets OV, MacLennan GT, Singh R, Bhaskaran S, Shukla S, **Gupta S**: High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF- κ B. *Prostate* 72:233-43, 2012 [PMID:21604287](#)
90. Thakur VS, Gupta K, **Gupta S**: Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. *Carcinogenesis* 33:377-84, 2012 [PMID:22114073](#)
91. Nawab A, Thakur VS, Yunus M, Mahdi A, **Gupta S**: Selective cell cycle arrest and induction of apoptosis in human prostate cancer cells by polyphenol-rich extract of *Solanum nigrum*. *Int J Mol Med.* 29:277-84, 2012 [PMID:22076244](#)
92. Kanwal R, **Gupta S**: Epigenetic modifications in cancer. *Clin Genet.* 81:303-11, 2012 [PMID:22082348](#)
93. Pandey M, Kaur P, Shukla S, Abbas A, Fu P, **Gupta S**: Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study. *Mol Carcinogenesis*, 51(12):952-62, 2012 [PMID:22006862](#)
94. Shukla S, MacLennan GT, Fu P, **Gupta S**: Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model. *Pharm Res.* 29(6):1506-17, 2012 [PMID:22139534](#)
95. Thakur VS, Gupta K, **Gupta S**: Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. *Int. J Oncol.*, 41(1):353-61, 2012 [PMID:22552582](#)
96. Bhaskaran N, Shukla S, Kanwal R, Srivastava JK, **Gupta S**: Induction of heme oxygenase-1 by chamomile protects murine macrophages against oxidative stress. *Life Sci.* 90(25-26):1027-33, 2012 [PMID:22683429](#)
97. Vykhovanets EV, MacLennan GT, Vykhovanets OV, Cherullo EE, Ponsky LE, **Gupta S**. Molecular imaging of nuclear factor- κ B in bladder as a primary regulator of inflammatory response. *J Urol.* 187(1):330-7, 2012 [PMID:22099998](#)
98. Bhaskaran N, Srivastava JK, Shukla S, **Gupta S**. Chamomile confers protection against hydrogen peroxide-induced toxicity through activation of Nrf2-mediated defense response *Phytother Res.* 27(1):118-25, 2013 [PMID:22511316](#)
99. Bhaskaran N, Shukla S, Kanwal R, Srivastava JK, **Gupta S**. Induction of heme oxygenase-1 by chamomile protects murine macrophages against oxidative stress *Life Sci.* 90(25-26):1027-33, 2012 [PMID:22683429](#)
100. Gupta K, Thakur VS, Bhaskaran N, Nawab A, Babcook MA, Jackson MW, **Gupta S**. Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. *PLoS One* 7(12):e52572, 2012 [PMID:23285096](#)
101. Babcook MA, **Gupta S**. Apigenin modulates insulin-like growth factor axis: Implications for prevention and therapy of prostate cancer. *Curr Drug Targets.* 2012 Nov 6. [Epub ahead of print] [PMID:23140291](#)
102. Shukla S, Sharma H, Abbas A, MacLennan GT, Fu P, Danielpour D, **Gupta S**. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. *PLoS One* 8(1):e53527, 2013 [PMID:23308245](#)
103. Lin P-Y, Cheng K-L, McGuffin-Cawley JD, Shieu F-S, Samia AC, **Gupta S**, Cooney MM, Thompson CL, Liu CC: Detection of alpha-methylacyl-CoA racemase (AMACR), a biomarker of prostate cancer, in

- patient blood samples using a nanoparticle electrochemical biosensor. *Biosensors* 2(4), 377-387, 2012 [PMID:25586028](#)
104. Deb G, Thakur VS, **Gupta S**. Multifaceted role of EZH2 in breast and prostate cancer – Epigenetics and beyond. *Epigenetics*, 8(5):464-76, 2013 [PMID:23644490](#)
 105. Shukla S, Bhaskaran N, MacLennan GT, **Gupta S**. Deregulation of FoxO3a Accelerates Prostate Cancer Progression in TRAMP Mice. *Prostate*. 73(14):1507-17, 2013 [PMID:23765843](#)
 106. Kanwal R, Pandey M, Bhaskaran N, MacLennan GT, Fu P, Ponsky LE, **Gupta S**. Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1. *Mol Carcinog*. 53(1):8-18, 2014 [PMID:22833520](#)
 107. Shukla S, Bhaskaran N, Babcook MA, Fu P, MacLennan GT, Gupta S. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. *Carcinogenesis* 35(2):452-60, 2014 [PMID:24067903](#)
 108. Thakur VS, Deb G, Babcook MA, **Gupta S**. Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. *AAPS J*. 16(1):151-63, 2014 [PMID:24307610](#)
 109. Shukla S, Fu P, **Gupta S**. Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. *Apoptosis* 19(5):883-94, 2014 [PMID:24563225](#)
 110. Sharma H, Kanwal R, Bhaskaran N, **Gupta S**. Plant flavone apigenin binds to nucleic acid bases and reduces oxidative DNA damage in prostate epithelial cells. *PLoS One* 9(3):e91588, 2014 [PMID:24614817](#)
 111. Deb G, Singh AK, **Gupta S**. EZH2: Not EZHY (Easy) to Deal. *Mol Cancer Res*. 12(5):639-53, 2014 [PMID:24526064](#)
 112. Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP, Oak CZ, MacLennan GT, Flask CA, Lindner DJ, Parker Y, Daneshgari F, **Gupta S**. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. *Mol Cancer Ther*. 13(10):2288-302, 2014 [PMID: 25122066](#)
 113. Babcook MA, Sramkoski RM, Fujioka H, Daneshgari F, Almasan A, Shukla S, Nanavaty RR, **Gupta S**. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. *Cell Death Dis*. 5:e1536, 2014 [PMID:25412314](#)
 114. He Q, Wang H, Yue Z, Yang L, Tian J, Liu G, **Gupta S**, Daneshgari F, Wang Z. Waist circumference and risk of lower urinary tract symptoms: a meta-analysis. *Aging Male* 17(4):223-9, 2014 [PMID:25295871](#)
 115. Deb G, Thakur VS, Limaye AM, **Gupta S**. Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells. *Molecular Carcinogenesis* 54(6):485-499, 2015 [PMID:24481780](#)
 116. Tomechko SE, Liu G, Tao M, Schlatter D, Powell CT, **Gupta S**, Chance MR, Daneshgari F. Tissue specific dysregulated protein subnetworks in type 2 diabetic bladder urothelium and detrusor muscle. *Mol Cell Proteomics* 14(3):635-45, 2015 [PMID: 25573746](#)
 117. Kanwal R, Gupta K, **Gupta S**. Cancer epigenetics: an introduction. *Methods Mol Biol*. 1238:3-25. 2015 PubMed [PMID:25421652](#)
 118. Shukla S, Kanwal R, Shankar E, Datt M, Chance MR, Fu P, MacLennan GT, **Gupta S**. Apigenin blocks IKK α activation and suppresses prostate cancer progression. *Oncotarget* 6(31):31216-32, 2015 [PMID:26435478](#)
 119. Singh S, Shukla GC, **Gupta S**. MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer. *Curr Pharmacol Rep*. 1(2):79-88, 2015 [PMID:25774339](#)
 120. Shankar E, Bhaskaran N, MacLennan GT, Liu G, Daneshgari F, **Gupta S**. Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases. *J Urol Res*. 2(1), 2015 [PMID:26417612](#)

121. Shukla S, Shankar E, Fu P, MacLennan GT, **Gupta S**. Suppression of NF- κ B and NF- κ B-Regulated Gene Expression by Apigenin through I κ B α and IKK Pathway in TRAMP Mice. PLoS One. 10(9):e0138710, 2015 [PMID: 26379052](#)
122. He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, **Gupta S**. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis. 19(1):7-13, 2016 [PMID:26391088](#)
123. Singh S, Zheng Y, Jagadeeswaran G, Ebron JS, Sikand K, **Gupta S**, Sunker R, Shukla GC. Deep sequencing of small RNA libraries from human prostate epithelial and stromal cells reveal distinct pattern of microRNAs primarily predicted to target growth factors. Cancer Lett. 371(2):262-73, 2016 [PMID:26655274](#)
124. Shukla GC, Plaga AR, Shankar E, **Gupta S**. Androgen receptor-related diseases: what do we know? Andrology. 4(3):366-81, 2016 [PMID:26991422](#)
125. He Q, Babcook MA, Shukla S, Shankar E, Wang Z, Liu G, Erokwa BO, Flask CA, Lu L, Daneshgari F, MacLennan GT, **Gupta S**. Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model. Prostate. 76(11):964-76, 2016 [PMID:27040645](#)
126. Babcook MA, Joshi A, Montellano JA, Shankar E, **Gupta S**. Statin Use in Prostate Cancer: An Update. Nutr Metab Insights. 9:43-50, 2016 [PMID:27441003](#)
127. Chen L, Li J, Farah E, Sarkar S, Ahmad N, **Gupta S**, Lerner J, Liu X. Co-targeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. Mol Cancer Ther. 15(9):2107-18, 2016 [PMID:27390342](#)
128. Shankar E, Kanwal R, Candamo M, Gupta S. Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges. Semin Cancer Biol. S1044-579X(16)30011-6, 2016 [PMID:27117759](#)
129. Kanwal R, Datt M, Liu X, **Gupta S**. Dietary Flavones as Dual Inhibitors of DNA Methyltransferases and Histone Methyltransferases. PLoS One. 11(9):e0162956. 2016 [PMID:27658199](#)
130. Shankar E, Zhang A, Franco D, **Gupta S**. Betulinic acid-mediated apoptosis in human prostate cancer cells involves p53 and nuclear factor-kappa B (NF- κ B) pathways. Molecules. 22(2), 2017 [PMID:28208611](#)
131. Estemalik J, Demko C, Bissada NF, Joshi N, Bodner D, Shankar E, **Gupta S**. Simultaneous detection of oral pathogens in subgingival plaque and prostatic fluid of men with periodontal and prostatic diseases. J Periodontol. 88(9):823-829, 2017 [PMID:28548883](#)
132. Kanwal R, Plaga AR, Liu X, Shukla GC, **Gupta S**. MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Lett. 407:9-20, 2017 [PMID:28823964](#)
133. Glover M, Soni S, Ren Q, MacLennan GT, Fu P, **Gupta S**. Influence of chronic inflammation on Bcl-2 and PCNA expression in prostate needle biopsy specimens. Oncol Lett. 14(4):3927-3934, 2017 [PMID:28943900](#)
134. Gupta K, **Gupta S**. Neuroendocrine differentiation in prostate cancer: key epigenetic players. *Editorial*. Translational Cancer Res. 6(1): S104-108, 2017
135. Shankar E, Goel A, Gupta K, Gupta S. Plant flavone apigenin: An emerging anticancer agent. Curr Pharmacol Rep. 3(6):423-446. 2017 [PMID:29399439](#)
136. Gupta K, Montellano J, **Gupta S**. Cancer chemoprevention with natural agents: Where we are now? *Editorial*. J Nat Agents and Mol Ther. 2018; 1(1):1-3, 2018
137. Shukla GC, **Gupta S**. Hallmarks of cancer- focus on RNA metabolism and regulatory noncoding RNAs. Cancer Lett. 420:208-209, 2018 [PMID:29409790](#)
138. Shukla GC, **Gupta S**. RNA biology-featuring the special issue guest editors "Cancer Letters". Cancer Lett. 421:41-42, 2018 [PMID:29452145](#)
139. Babcook MA, Akgul M, Margevicius S, MacLennan GT, Fu, P, Abouassaly R, **Gupta S**. Ser-486/491 phosphorylation and inhibition of AMPK α activity is positively associated with Gleason score, metastasis,

- and castration-resistance in prostate cancer: A retrospective clinical study. *Prostate*. 2018 Mar 26. doi: 10.1002/pros.23515. [Epub ahead of print] [PMID:29577356](#)
140. Leo P, Shankar E, Elliott R, Janowczyk A, Madabhushi A, Gupta S. Combination of nuclear NF- κ B/p65 localization and gland morphological features from surgical specimens appears to be predictive of early biochemical recurrence in prostate cancer patients. *Proc. SPIE 10581, Medical Imaging 2018: Digital Pathology*, 105810D (6 March 2018); <https://doi.org/10.1117/12.2292652>
 141. Arterbery E, **Gupta S**. Apigenin as an anti-aging skin treatment. *Journal of Clinical and Cosmetic Dermatology J Clin Cosmet Dermatol.*, 2018 2(2): [dx.doi.org/10.16966/2576-2826.1282018](https://doi.org/10.16966/2576-2826.1282018)
 142. Zhang Z, Cheng L, Li J, Farah E, Atallah N, Pascuzzi P, **Gupta S**, Liu X. Inhibition of the Wnt/ β -catenin pathway overcomes resistance of enzalutamide in castration-resistant prostate cancer. *Cancer Res.* 78(12):3147-3162, 2018 [PMID:29700003](#)
 143. Kanwal R, Shukla S, Walker E, **Gupta S**. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics. *Cancer Lett.* 430:25-33, 2018 [PMID:29775627](#)
 144. Chatterjee A, **Gupta S**. The multifaceted role of glutathione S-transferases in cancer. *Cancer Lett.* 433:33-42, 2018 [PMID:29959055](#)
 145. Leo P, Elliott R, Shih NNC, Gupta S, Feldman M, Madabhushi A. Stable and discriminating features are predictive of cancer presence and Gleason grade in radical prostatectomy specimens: a multi-site study. *Sci Rep.* 8(1):14918, 2018 [PMID:30297720](#)
 146. Da Silva APB, Alluri LSC, Bissada NF, **Gupta S**. Association between oral pathogens and prostate cancer: building the relationship. *Am J Clin Exp Urol.* 7(1):1-10, 2019 [PMID:30906801](#)
 147. Deb G, Shankar E, Thakur VS, Ponsky LE, Bodner DR, Fu P, **Gupta S**. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes. *Mol Carcinog.* 2019 Mar 10. doi: 10.1002/mc.23003. [Epub ahead of print] [PMID:30854739](#)
 148. Shankar E, Weis MC, Avva J, Shukla S, Shukla M, Sreenath SN, **Gupta S**. Complex systems biology approach in connecting PI3K-Akt and NF- κ B pathways in prostate cancer. *Cells.* 2019 Feb 26;8(3). pii: E201. [PMID:30813597](#)
 149. Verma S, **Gupta S**. Noncoding RNAs and its implication as biomarkers in renal cell carcinoma: A systematic analysis. *Ann Urol Oncol* 2019; <https://doi.org/10.32948/>
 150. Chen W, Jia L, **Gupta S**, MacLennan GT. The role of chronic inflammation in prostate carcinogenesis: A follow-up study. *Ann Urol Oncol* 2019; <https://doi.org/10.32948/auo.2019.01.14>
 151. Verma S, Shukla S, Pandey M, MacLennan GT, Gupta S. Differentially expressed genes and molecular pathways in an autochthonous mouse prostate cancer model. *Front. Genet.* 10:235. [doi:10.3389/fgene.2019.00235](https://doi.org/10.3389/fgene.2019.00235)
 152. Ebron JS, Shankar E, Singh J, Sikand K, Weyman CM, **Gupta S**, Lindner DJ, Liu X, Campbell MJ, Shukla GC. MicroRNA-644a disrupts oncogenic transformation by regulating the androgen signaling, Warburg effect, and other tumorigenic pathways. *Cancer Res.* 2019 Feb 26. pii: canres.2993.2018. [Epub ahead of print] [PMID:30808676](#)

BOOK CHAPTERS

1. **Gupta S**, Husain MM, and Srivastava RC: Implication of nitric oxide in nickel-induced hyperglycemia in rats. **The Biology of Nitric Oxide**. [Ed: Moncada S et al.] Portland Press, London Vol. 6., 177, 1998
2. Shukla S and **Gupta S**: Apigenin in health and disease with special reference to cancer chemoprevention in “**Herbal Drugs: A Twenty First Century Perspective**”. Chapter 18, 2009

3. Shukla S and **Gupta S**: Role of apigenin in human health and disease. "**Beer in Health and Disease Prevention**" Edited by Victor E Preedy ISBN: 978-0-12-373891-2, Elsevier Inc., Academic Press, 2009
4. Srivastava JK and **Gupta S**: Health promoting benefits of chamomile in the elderly population. "**Complementary and Alternative Therapies in the Aging Population**", Edited by Ronald R Watson ISBN: 978-0-12-374228-5, Elsevier Inc., Academic Press, 2009
5. Shukla S and **Gupta S**: Molecular targets and therapeutic uses of coriander. "**Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine**", ISBN: 13-978-981-283-790-5, Stallion Press, 2009
6. Srivastava JK and **Gupta S**: Health benefits of chamomile. "**Recent Progress in Medicinal Plants**", Vol 27, Edited by Awaad AS, Govil JN, Singh VK, Studium Press LLC, USA, 2009
7. Shukla S and **Gupta S**: Apigenin and cancer chemoprevention. "**Bioactive Foods in Promoting Health: Individual Fruits in Disease and Cancer**", Edited by Ronald R Watson ISBN: 978-0-123-74628-3, Elsevier Inc., Academic Press, 2009
8. Thakur VS and **Gupta S**: Chemopreventive action of green tea polyphenols (Molecular-biological mechanisms) "**Green Tea Polyphenols: Nutraceuticals of Modern Life**", Taylor & Francis, Edited by Juneja LR, Kapoor MP, Okubo T, Rao T. ISBN 978-1-43-984788-6, CRC Press, 2012
9. Shukla S and **Gupta S**: Current status and future prospects of nutraceuticals in prostate cancer. In "**Nutraceuticals and Cancer**" Edited by Fazlul H Sarkar, Springer, ISBN 978-94-007-2629-1, Chapter 5, pp 77-110 2012
10. Thakur VS and **Gupta S**: Dietary phytochemicals as epigenetic modulators in cancer in "**Nutrition, Diet and Cancer**" Springer Edited by Shankar S, Srivastava RK. ISBN 978-94-007-2922-3, Chapter 19, 496-515, 2012
11. Babcook MA and **Gupta S**: Apigenin: A promising anticancer agent for the modulation of the insulin-like growth factor (IGF) axis in prostate cancer. Special Issue: "**Cancer Metabolism**", In memory of Erich Eigenbrodt. Edited by Qayyum MA Biomedical Research, 23 SI 55-68, 2012
12. Thakur VS, and **Gupta S**: Plant Polyphenols as Epigenetic Modulators of GSTP1 Activity in Prostate Cancer. In the book series "**Epigenetics and Cancer**" publisher Springer, Edited by Fazlul H Sarkar, ISBN 978-94-007-6611-2, Chapter 13, 231-250, 2013
13. Thakur VS and **Gupta S**. Chemopreventive action of green tea polyphenols (Molecular-biological mechanisms) Green Tea Polyphenols: "**Nutraceuticals of Modern Life**" Taylor & Francis, Edited by Juneja LR, Kapoor MP, Okubo T, Rao T. ISBN 978-1-43-984788-6, CRC Press, 2012
14. Shukla S and **Gupta S**. Current status and future prospects of nutraceuticals in prostate cancer. In "**Nutraceuticals and Cancer**" Edited by Fazlul H Sarkar, Springer, ISBN 978-94-007-2629-1, Chapter 5, pp 77-110 2012
15. Srivastava JK, **Gupta S**. Chamomile: A Herbal Agent for the Treatment of Old Age Diseases. In the book entitled: "**Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults**" Elsevier Eds. ISBN: 978-0-12-418680-4, Chapter 18, 171-183, 2015
16. Deb G, Gupta S. Natural Phytochemicals as Epigenetic Modulators. In the book entitled "**Genomics, Proteomics and Metabolomics in Nutraceuticals and Functional Foods**" Second Edition Edited by Debasis Bagchi, Anand Swaroop, and Manashi Bagchi, Wiley-Interscience, 2015
17. Shankar E, Candamo M, MacLennan GT, **Gupta S**. Maspin expression and its metastasis suppressing function in prostate cancer. In the book entitled "**Prostate Cancer-Leading Edge Diagnostic Procedures and Treatments**" Edited by Dr. Ravinder Mohan, Intech Eds. ISBN: 978-953-51-2644-7, Chapter 12, 197-212, 2016
18. Shankar E and **Gupta S**. Nutritional and Lifestyle Impact on Epigenetics and Cancer. In the book entitled: "**Epigenetics Energy Balance and Cancer**" Edited by Dr. Nathan A Berger, Springer Eds. ISBN: 978-3-319-41608-3, Chapter 4, 75-108, 2016

19. Shankar E, Montellano J, **Gupta S**. Green tea polyphenols in the prevention and therapy of prostate cancer Edited by Dr. K. B. Harikumar, Francis & Taylor, CRC Press Eds. ISBN: 13-978-1-4987-2987-1, Chapter 5, 111-124, 2016

PUBLISHED ABSTRACTS

** Award Winning Posters/Podium presentations

1. Behari JR, **Gupta S**, and Srivastava RC: Use of liposome 2, 3-dimercapto propane-1-sulphonic acid sodium salt (DMPS) in the treatment of mice loaded with cadmium. 2nd National Symposium and Workshop on Liposome Research at Delhi University, South Campus, New Delhi, India, 1989
2. Srivastava S, **Gupta S**, Behari JR, and Srivastava RC: Use of liposome as carriers of chelating agents (DMPS) to potentiate its efficacy for cadmium detoxification. 8th National Conference of Society of Toxicology and Workshop on Reproductive Toxicology at Udaipur, India, 1989
3. Behari JR, Srivastava S, **Gupta S**, and Srivastava RC: Effect of liposome encapsulated 2, 3-dimercapto succinic acid (DMSA) on biochemical alterations and copper and zinc levels in cadmium exposed rats. 9th National Conference of Society of Toxicology at Ahmedabad, India, 1990
4. Srivastava S, Behari JR, **Gupta S**, and Srivastava RC: Alterations in liposomal lipid peroxidation in presence of nickel by incorporation of α -tocopherol in the lipid bilayer. 3rd International Symposium on Biological Oxidation and Polyunsaturated Fatty Acids at Trivandrum, India, 1990
5. **Gupta S**, Athar M, Behari JR, and Srivastava RC: Cadmium-mediated induction of cellular defence mechanisms. 9th National Conference of Society of Toxicology at Ahmedabad, India, 1990
6. Behari JR, Srivastava S, **Gupta S**, and Srivastava RC: Liposomes as carriers of metal chelating agents. 3rd National Symposium on Liposome Research at University of Delhi, South Campus, New Delhi, India, 1991
7. **Gupta S**, Hasan SK, and Srivastava RC: Relative efficacy of various chelating agents in acute cadmium poisoning. 2nd Congress of Toxicology in Developing Countries at New Delhi, India 1991
8. Srivastava S, Behari JR, **Gupta S**, and Srivastava RC: Influence of DMSA esters administered *via* liposomes on biochemical alterations and levels of cadmium in pre exposed rats. 2nd Congress of Toxicology in Developing Countries at New Delhi, India, 1991
9. Behari JR, **Gupta S**, Srivastava S, and Srivastava RC: Role of lipid composition on carrier potential of liposomes encapsulating chelating drugs. 2nd Congress of Toxicology in Developing Countries at New Delhi, India, 1991
10. Behari JR, Srivastava S, **Gupta S**, and Srivastava RC: Modulations in size and composition of liposomes to potentiate the efficacy of encapsulated chelating agents. 4th National Symposium on Liposome Research at University of Delhi, South Campus, New Delhi, India, 1992
11. **Gupta S**, Husain MM, Hasan SK, and Srivastava RC: Does vanadium scavenge reactive oxygen species in vivo? 1st International Conference in Health and Disease; Effects of Essential and Toxic Trace Elements at Jamia Hamdard University, Delhi, India, 1993
12. **Gupta S**, Pratap VB, Hasan SK, Husain MM, Farookh A, and Srivastava RC: Impact of nutritional and environmental factors in initiation of cataract formation. 13th Annual Conference of Society of Toxicology at Bhubneshwer, Orissa, India, 1994
13. Pratap VB, **Gupta S**, Farookh A, Hasan SK, Ahmad N, Husain MM, and Srivastava RC: Impact of air pollution on human lungs and eyes. 3rd Congress of Toxicology in Developing Countries at Cairo, Egypt 1995
14. **Gupta S**, Husain MM, Mohan RR, Hasan SK, and Srivastava RC: Reversal of nickel-mediated hyperglycemia by zinc metallothionein. 15th Annual Conference of Society of Toxicology at Calcutta, India, 1996

15. Husain MM, **Gupta S**, Hasan SK, Mohan RR, and Srivastava RC: Effect of zinc pretreatment on blood glucose and biochemical and trace metal alterations in pancreas after nickel exposure in rats. 15th Annual Conference of Society of Toxicology at Calcutta, India, 1996
16. ****Gupta S**, Husain MM, and Srivastava RC: Implication of nitric oxide in nickel-induced hyperglycemia in rats. 5th International Meeting on Biology of Nitric Oxide at Kyoto, Japan, 1997
17. **Gupta S**, Mohan RR, Srivastava RC, and Pratap VB: Risk assessment in human eyes and lungs due to auto exhaust. National Workshop on Environmental Impact Assessment, Policy, Practice and Prospects for India at Centre for Environment Education, NRC, Lucknow, India, 1997
18. Pradhan S, **Gupta S**, Bhargava SK, and Pratap VB: Air quality assessment in Lucknow city. National Workshop on Environmental Impact Assessment, Policy, Practice and Prospects for India at Centre for Environment Education, NRC, Lucknow, India, 1997
19. Mohan RR, **Gupta S**, Srivastava RC, and Pratap VB: Clinical and Toxicological studies on human subjects affected by auto exhaust. National Workshop on Environmental Impact Assessment, Policy, Practice and Prospects for India at Centre for Environment Education, NRC, Lucknow, India, 1997
20. Mukhtar H, **Gupta S**, and Ahmad N: Inhibition of nuclear transcription factor NF- κ B by green tea constituent epigallocatechin-3-gallate in human epidermoid carcinoma cells A431. 59th Annual Meeting of International Investigative Dermatology at Cologne, Germany 1998
21. Ahmad N, **Gupta S**, and Mukhtar H: Photodynamic therapy-induced apoptosis is mediated by activation of CD-95 (FAS/APO-1). 59th Annual Meeting of International Investigative Dermatology at Cologne, Germany 1998
22. Mukhtar H, **Gupta S**, and Ahmad N: Cancer chemoprevention by polyphenolic antioxidants in green tea. World Congress of Oxygen Club of California at Santa Barbara, California, USA 1998
23. ****Gupta S**, Ahmad N, and Mukhtar H: Nitric oxide may be involved in photodynamic therapy-mediated apoptosis. 26th Annual Meeting of American Society for Photobiology at Snowbird, Utah, USA 1998
24. Ahmad N, **Gupta S**, and Mukhtar H: Involvement of FAS/CD-95/APO-1 in photodynamic therapy-mediated apoptosis. 26th Annual Meeting of American Society for Photobiology at Snowbird, Utah, USA 1998
25. ****Gupta S**, Ahmad N, and Mukhtar H: Green tea constituent epigallocatechin-3-gallate mediates apoptosis and cell cycle arrest in both hormone dependent and independent human prostate cancer cells. Society of Toxicology Symposium on "The Role of Diet and Caloric Intake in Aging, Obesity, and Cancer" at Reston, VA, USA 1998
26. Ahmad N, **Gupta S**, and Mukhtar H: Antiproliferative effect of green tea constituent epigallocatechin-3-gallate is mediated by nuclear transcription factor NF κ B. Society of Toxicology Symposium on "The Role of Diet and Caloric Intake in Aging, Obesity, and Cancer" at Reston, VA, USA 1998
27. Ahmad N, **Gupta S** and Mukhtar H: Photodynamic therapy-induced apoptosis is mediated by activation of CD-95 (FAS/APO-1). J Invest Dermatol 110:692, 1998
28. Mukhtar H, **Gupta S** and Ahmad N: Inhibition of nuclear transcription factor NF- κ B by green tea constituent epigallocatechin-3-gallate in human epidermoid carcinoma cells A431. J. Invest Dermatol 110:521, 1998
29. ****Gupta S**, Ahmad N and Mukhtar H: Nitric oxide may be involved in photodynamic therapy-mediated apoptosis. Photochem. Photobiol. 67:89S-90S, 1998
30. Ahmad N, **Gupta S** and Mukhtar H: Involvement of FAS/CD-95/APO-1 in photodynamic therapy-mediated apoptosis. Photochem. Photobiol. 67:69S-70S, 1998
31. Ahmad N, **Gupta S** and Mukhtar H: Suppression of nuclear transcription factor (NF- κ B)-activation by green tea polyphenol (-)-epigallocatechin-3-gallate. Proc. Amer. Assoc. Cancer Res. 40:532, 1999

32. ****Gupta S**, Ahmad N and Mukhtar H: Epigallocatechin-3-gallate-caused G0/G1-phase cell cycle arrest and apoptosis in human prostate carcinoma cells is mediated by the induction of WAF/1p21. Proc. Amer. Assoc. Cancer Res. 40:532, 1999
33. Sakamoto K, Ahmad N, **Gupta S**, Hara Y and Mukhtar H: Synergy of black and green tea polyphenols with genistein in inhibiting human prostate cancer cell growth. Proc. Amer. Assoc. Cancer Res. 40:531, 1999
34. **Gupta S**, Ahmad N, MacLennan GT, Greenberg NM and Mukhtar H: Prevention against prostate cancer development and its metastases by α -difluoromethylornithine in transgenic adenocarcinoma mouse prostate (TRAMP) model that mimics human disease. LB-15 Late Breaking Abstract, 90th Annual AACR meeting, 1999
35. **Gupta S**, Colussi VC, Feyes DK, Greenberg NM and Mukhtar H: P53-mediated induction of P21/WAF1 and apoptosis during phthalocyanine (Pc4) photodynamic therapy of prostate cancer in transgenic mice. Photochem. Photobiol. 69:8S, 1999
36. Mukhtar H, Ahmad N, and **Gupta S**: Green tea in chemoprevention of prostate cancer. 4th World Congress on Advances in Oncology and 2nd International Symposium on Molecular Medicine at Vouliagmeni, Athens, Greece 1999
37. Sakamoto K, Ahmad N, **Gupta S**, Hara Y, and Mukhtar H: Synergy of (-)-epigallocatechin-gallate (EGCG) and genistein in inhibiting human prostate tumor cell growth *in vitro* and *in vivo*. 2nd International Conference on Food Factors-Chemistry and Health Promotion at Kyoto, Japan 1999
38. Ahmad N, **Gupta S**, and Mukhtar H: Sanguinarine is an effective inhibitor of proliferation of skin cancer cells: Involvement of nuclear factor kappa B. J. Invest. Dermatol., 114:765, 2000
39. ****Gupta S**, Ahmad N, Lewin JS, Greenberg NM and Mukhtar H: Chemoprevention of prostate cancer in tramp mice by oral infusion of green tea polyphenols. Proc. Amer. Assoc. Cancer Res. 41:531, 2000
40. Srivastava M, **Gupta S**, Bostwick DG, Ahmad N and Mukhtar H: Overexpression of lipooxygenase-5 in human prostate adenocarcinoma. Proc. Amer. Assoc. Cancer Res. 41:46, 2000
41. **Gupta S**, Husain MM, Ahmad N, Hastak K, Marengo SR and Mukhtar H: Antitumor efficacy of green tea constituent epigallocatechin-3-gallate (EGCG) in androgen-dependent and -independent human prostate tumor xenografts in athmic nude mice: A relationship with levels of circulating prostate specific antigen (PSA). Proc. Amer. Assoc. Cancer Res. 41:533, 2000
42. **Gupta S**, Afaq F and Mukhtar H: Apigenin in chemoprevention of prostate cancer. Proc. Amer. Assoc. Cancer Res., 42:140, 2001
43. Ahmad N, Adhami V, **Gupta S**, Greenberg N and Mukhtar H: Involvement of matrix metalloproteinase as a mechanism of inhibition of prostate cancer development and its metastasis by green tea polyphenols in TRAMP Mice. Proc. Amer. Assoc. Cancer Res., 42:141, 2001
44. Hastak K, Ahmad N, **Gupta S**, Agarwal M and Mukhtar H: Role of p53 in anti-proliferative effect of epigallocatechin-3-gallate. Proc. Amer. Assoc. Cancer Res., 42:224, 2001
45. **Gupta S**, Hastak K, Rao JS and Mukhtar H: Overexpression of nitric oxide synthase-2 in human prostate adenocarcinoma: Implication for angiogenesis and disease progression. Proc. Amer. Assoc. Cancer Res., 42:942, 2001
46. Ahmad N, **Gupta S**, Cheng P and Mukhtar H: Involvement of retinoblastoma and E2F transcription factors during epigallocatechin-3-gallate-mediated cell cycle dysregulation and apoptosis of human epidermoid carcinoma A431 cells. J. Invest Dermatol. 117:479, 2001
47. **Gupta S**, Hastak K, Ahmad N and Mukhtar H: The role of caspases in execution of apoptosis in human epidermoid carcinoma A431 cells by green tea polyphenols (-)-epigallocatechin-3-gallate. J. Invest. Dermatol., 117:479, 2001
48. Mukhtar H, Ahmad N and **Gupta S**: Sequence of events during photodynamic therapy-mediated apoptosis of human epidermoid carcinoma A431 cells. J. Invest. Dermatol. 117:538, 2001

49. Mukhtar H and **Gupta S**: Green tea in chemoprevention of prostate cancer. *Mutation Res.* 483:S17, 2001
50. Afaq, F, Adhami FM, Ahmad N, **Gupta S** and Mukhtar H: Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits ultraviolet B-mediated activation of nuclear factor kappa B in cultured human epidermal keratinocytes. *Proc. Amer. Assoc. Cancer Res.*, 43:1143, 2002
51. ****Gupta S**, Hussain T, MacLennan GT, Patel J and Mukhtar H: Calcium binding proteins S100A2 and S100A4 as potential prognostic markers for progression of human prostate adenocarcinoma. *Proc. Amer. Assoc. Cancer Res.*, 43:1, 2002
52. Hastak K, **Gupta S**, Ahmad N and Mukhtar H: Green tea polyphenol, epigallocatechin-3-gallate induces apoptosis in LNCaP cells by stabilization of p53 and modulation of Bax/Bc12 ratio. *Proc. Amer. Assoc. Cancer Res.*, 43:166, 2002
53. Hussain T, **Gupta S** and Mukhtar H: Green tea polyphenol, (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. *Proc. Amer. Assoc. Cancer Res.*, 43:166, 2002
54. **Gupta S**, Adhami VM, Lewin JS and Mukhtar H: Dietary supplementation of selective COX-2 inhibitor celecoxib suppresses prostate carcinogenesis in TRAMP mice. *Proc. Amer. Assoc. Cancer Res.*, 43:671, 2002
55. Shukla S and **Gupta S**: Molecular pathway for apigenin-induced cell cycle arrest and apoptosis of human prostate carcinoma DU145 cells. *Research Show CASE 2003, CWRU*, 2003
56. Trokhan S and **Gupta S**: Anti-Proliferative Effects of D-Limonene on Human Prostate Carcinoma Cells. *Proc. Amer. Assoc. Cancer Res.*, 44:1111, 2003
57. Saleem M, Adhami VM, Ahmad N, **Gupta S** and Mukhtar H: Calcium binding protein S100A4 is upregulated in advanced prostate cancer in TRAMP: Significant down regulation by oral feeding of green tea. *Proc. Amer. Assoc. Cancer Res.*, 44:1099, 2003
58. Adhami VM, Siddiqui IA, Ahmad N, **Gupta S** and Mukhtar H: Inhibition of IGF-I induced autocrine signaling in TRAMP mice by oral infusion of green tea polyphenols. *Proc. Amer. Assoc. Cancer Res.*, 44:1099, 2003
59. Shukla S, MacLennan GT, Fu Ping, Patel J, Marengo SR, Resnick MI and **Gupta S**: Constitutive activation of NF- κ B/p65 (Rel A) in human prostate adenocarcinoma: Relevance with disease progression. *Proc. Amer. Assoc. Cancer Res.*, 45:231, 2004
60. Shukla S and **Gupta S**: Apigenin inhibits constitutive and TNF α -mediated NF- κ B activation and induces apoptosis in human prostate carcinoma PC-3 cells: Correlation with NF- κ B responsive genes. *Proc. Amer. Assoc. Cancer Res.*, 45:2240, 2004
61. ****Gupta S**, Shukla S, MacLennan GT, Jain S, Resnick MI and Seftel AD: Chronic inflammation as inductor of prostate carcinogenesis: A needle Biopsy study. *Proc. Amer. Assoc. Cancer Res.*, 45:1773, 2004
62. Shukla S, MacLennan GT, Patel J, Resnick MI and **Gupta S**: A mechanism of prostate cancer progression through activation of Akt/Protein kinase B survival signaling pathway. *Late Breaking Abstract-LB45 Proc. Amer. Assoc. Cancer Res.*, 45:66, 2004
63. Shukla S, Fu Ping, Mishra A, Resnick MI and **Gupta S**: Oral intake of Apigenin inhibits Growth of 22Rv1 human prostate cancer xenograft in athymic Nude mice. *Late Breaking Abstract-LB320 Proc. Amer. Assoc. Cancer Res.*, 45:131, 2004
64. Shukla S, MacLennan GT, Patel J, Resnick MI and **Gupta S**: Constitutive NF- κ B activation in human prostate cancer is mediated by Akt/Protein kinase B. *Research Show CASE, CWRU*, 2004
65. **Gupta S**, Shukla S, MacLennan GT, Fu Ping, Patel J, Marengo SR and Resnick MI: Constitutive activation of NF- κ B/p65 (Rel A) in human prostate adenocarcinoma and its correlation with disease progression. *Research Show CASE, CWRU*, 2004

66. ****Gupta S**, Shukla S, Jain S, MacLennan GT, Seftel AD and Resnick MI: Chronic inflammation-induced cell survival and proliferation in pre-malignant lesions and incidental prostate carcinoma: A needle biopsy study. American Urological Association Annual Meeting at San Francisco, CA, May 8-13, 2004
67. Shukla S, Trokhan S, Resnick MI, and **Gupta S**: Epigallocatechin-3-gallate mediated reversal of GSTP1 CpG island hypermethylation leads to reactivation of GSTP1 expression in human prostate cancer cells. 3rd Annual Conference on Frontiers in Cancer Prevention Research, Seattle, WA, October 16-20, 2004
68. Shukla S, Flask C, Resnick MI, and **Gupta S**: Plant-flavonoid apigenin prevents development of prostate carcinogenesis in TRAMP mice. Research Show CASE CWRU, 2005
69. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, and **Gupta S**: Oral intake of apigenin leads to accumulation of human IGFBP-3 in 22Rv1 xenograft in athymic nude mice: Correlation with growth inhibition and induction of apoptosis. Research Show CASE, CWRU, 2005
70. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, and **Gupta S**: Upregulation of IGFBP-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. Proc. Amer. Assoc. Cancer Res., 96:5214, 2005
71. Shukla S, MacLennan GT, Marengo SR, Resnick MI, and **Gupta S**: Constitutive activation of PI3K-Akt and NF- κ B signaling pathway in transgenic adenocarcinoma of the mouse prostate model. Proc. Amer. Assoc. Cancer Res., 96:6072, 2005
72. Shukla S, MacLennan GT, Patel J, Marengo SR, Resnick MI, and **Gupta S**: Activation of PI3K-Akt signaling pathway leads to prostate cancer progression. Proc. Amer. Assoc. Cancer Res., 96:2324, 2005
73. Shukla S, Trokhan S, Resnick MI, and **Gupta S**: Epigallocatechin-3-gallate causes demethylation and activation of GSTP1 gene expression in human prostate cancer LNCaP cells. Proc. Amer. Assoc. Cancer Res., 96:1572, 2005
74. Hafeez BB, Ahmed S, Wang N, **Gupta S** and Haqqi TM: Green tea polyphenols (GTP) induce apoptosis in human osteosarcoma SAOS-2 cells through inhibition of nuclear factor- κ B (NF- κ B) activation. Proc. Amer. Assoc. Cancer Res., 96:5210, 2005
75. Shukla S, Flask C, Resnick MI, and **Gupta S**: Plant-flavonoid apigenin inhibits prostate carcinogenesis in TRAMP model. Late Breaking Abstract-LB318 Proc. Amer. Assoc. Cancer Res., 96:117, 2005
76. Pandey M and **Gupta S**: Green tea polyphenols (GTP) cause activation of the GSTP1 gene in prostate cancer LNCaP cells by promoter demethylation. Proc. Amer. Assoc. Cancer Res., 97:1614, 2006
77. Shukla S, MacLennan GT, Seftel AD and **Gupta S**: Activated form of Akt overrides androgen receptor signaling in MPAKT mice. Proc. Amer. Assoc. Cancer Res., 97:2820, 2006
78. Srivastava JK and **Gupta S**: Anti-proliferative and apoptotic effects of tocotrienol-rich fraction (TRF) of palm oil on prostate cancer cells. Proc. Amer. Assoc. Cancer Res., 97:3168, 2006
79. Shukla S, Flask CA, MacLennan GT, Pingfu F, Resnick MI and **Gupta S**: Inhibition of prostate carcinogenesis in TRAMP mice by oral intake of plant flavonoid apigenin. Proc. Amer. Assoc. Cancer Res., 97:3889, 2006
80. Shukla S, Patel DD and **Gupta S**: Induction of caspase-dependent, p53-mediated apoptosis by apigenin in 22Rv1 athymic nude mice tumor xenograft. Proc. Amer. Assoc. Cancer Res., 97:3939, 2006
81. Pandey M and **Gupta S**: High-throughput screening of methylation status of genes in prostate cancer using promoter methylation array. Late Breaking Abstract-LB126 Proc. Amer. Assoc. Cancer Res., 97:32, 2006
82. Srivastava JK, Shukla S, Shukla GC and **Gupta S**: Tocotrienol-rich fraction of palm oil inhibits growth of PC-3 tumor xenografts in athymic nude mice. Late Breaking Abstract-LB357 Proc. Amer. Assoc. Cancer Res., 97:95, 2006
83. Pandey M and **Gupta S**: Methylation status of genes in prostate cancer using high-throughput promoter array. Research ShowCASE# 542, CWRU, 2006

84. Shukla S, MacLennan GT, Resnick MI and **Gupta S**: Hyperactivation of Akt/ Protein Kinase B leads to prostate cancer cell invasion. Research ShowCASE# 543, CWRU, 2006
85. Srivastava JK and **Gupta S**: Palm oil TRF: A dietary supplement for the prevention of prostate cancer. Research ShowCASE# 544, CWRU, 2006
86. **MacLennan GT, Eisenberg R, Fleshman, RL, Taylor, JM., Fu P, Resnick MI, and **Gupta S**: Does chronic inflammation influences prostate carcinogenesis? A five year follow-up study. Proc. Amer. Urol. Asso. 175:35, 2006
87. Shukla S, MacLennan GT, Seftel AD, **Gupta S**: Increased phospho-Akt overrides androgen receptor signaling in MPAKT mice. Proc. Amer. Urol. Asso. 175:134, 2006
88. **Avva J, Weis M, Soebiyanto RP, Loparo KA, **Gupta S** and Sreenath SN: NF- κ B and PI3K/Akt pathway in prostate cancer. 7th International Conference on Systems Biology, Yokohama, Japan, 2006
89. **Gupta S**: Epigenetics and cancer chemoprevention: promise, prospects and challenges. International Conference on Frontiers of Pharmacology and Toxicology, Chicago, August 28-31, 2006
90. Vykhovanets Y, Shukla S, MacLennan, Resnick MI and **Gupta S**: Possible role of NF- κ B in cytokine-induced intraprostatic inflammation. Proceedings on 5th Annual Conference on Cytokine & Inflammation, 296, 2007
91. Pandey M and **Gupta S**: Green tea: A potent drink to prevent prostate cancer. Research ShowCASE#377, CWRU, 2007
92. Rabi T, Zhang A and **Gupta S**: Effect of betulinic acid against human prostate cancer. Research ShowCASE#378, CWRU, 2007
93. Shukla S, MacLennan GT, Flask CA, Fu P, Resnick MI and **Gupta S**: Blockade of β -catenin signaling by apigenin inhibits prostate cancer progression. Research ShowCASE#379, CWRU, 2007
94. Srivastava JK and **Gupta S**: Chamomile: From tea to tablet against cancer. Research ShowCASE#375, CWRU, 2007
95. Vykhovanets Y, Shukla S, MacLennan, Resnick MI and **Gupta S**: The nuclear factor-kappaB contributes in pro-inflammatory cytokine induced intraprostatic inflammation. Research ShowCASE#380, CWRU, 2007
96. Weis M, Avva J, Sreenath SN, Loparo KA, Shukla S and **Gupta S**: A systems approach to understanding the PI3K-Akt-NF- κ B pathway in prostate cancer. Research ShowCASE#417, CWRU, 2007
97. Kaur P and **Gupta S**: Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer cells. Research ShowCASE#376, CWRU, 2007
98. Pandey M and **Gupta S**: Aberrant CpG island hypermethylation of multiple genes in human prostate cancer. Proc. Amer. Assoc. Cancer Res., 98:1058, 2007
99. **Shukla S and **Gupta S**: Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 reactivation. Proc. Amer. Assoc. Cancer Res., 98:1576, 2007
100. Shukla S and **Gupta S**: Apigenin-mediated modulations of PI3K-Akt and MAPK signaling pathway causes growth inhibition and cell cycle arrest in human prostate cancer cells. Proc. Amer. Assoc. Cancer Res., 98:3350, 2007
101. **Shukla S, MacLennan GT, Flask CA, Fu P, Resnick MI and **Gupta S**: Plant flavonoid apigenin inhibits prostate carcinogenesis by suppressing β -catenin signaling pathways. Proc. Amer. Assoc. Cancer Res., 98:4197, 2007
102. Srivastava JK and **Gupta S**: Anti-proliferative and apoptotic effects of chamomile extract in various human cancer cells. Proc. Amer. Assoc. Cancer Res., 98:4207, 2007

103. Pandey M and **Gupta S**: Green tea polyphenols inhibit promoter hypermethylation through downregulation of DNMT expression in prostate cancer LNCaP cells. Late Breaking Abstract-LB212 Proc. Amer. Assoc. Cancer Res., 98:53, 2007
104. Vykhovanets EV, Shukla S, MacLennan GT, Resnick MI, Carlsen H, Blomhoff R and **Gupta S**: Molecular imaging of the transcription factor NF- κ B during cytokine-induced intraprostatic inflammation. Late Breaking Abstract-LB291 Proc. Amer. Assoc. Cancer Res., 98:74, 2007
105. Srivastava JK, Shukla S and **Gupta S**: Tocotrienol-rich fraction of palm oil leads to growth inhibition and apoptosis of PC-3 tumor xenografts in athymic nude mice. Proc. Amer. Urol. Asso. 176:138, 2007
106. ****Vykhovanets EV, Shukla S, MacLennan GT, Resnick MI, Carlsen H, Blomhoff R and Gupta S**: Possible role of nuclear factor-kappaB in intraprostatic inflammation. Proc. Amer. Urol. Asso. 176:92, 2007
107. ****Vykhovanets Y, Shukla S, MacLennan and Gupta S**: IL-1 β induced intraprostatic NF- κ B activation leads to up-regulation of chemoattractant signals that participate in leukocyte extravasation. Proceedings on 6th Annual Conference on Cytokine & Inflammation, 285, 2008
108. Srivastava JK and **Gupta S**: Chamomile suppresses inducible nitric oxide synthase and cyclooxygenase-2 through down-regulation of NF- κ B in LNCaP cells. Proc. Amer. Assoc. Cancer Res., 99:1263, 2008
109. Shukla S, MacLennan GT, Fu P and **Gupta S**: Apigenin block tumor growth, invasion and metastasis by upregulation of maspin in TRAMP model. Proc. Amer. Assoc. Cancer Res., 99:2114, 2008
110. Pandey M and **Gupta S**: Molecular mechanisms of GSTP1 reactivation by green tea polyphenols in LNCaP cells. Proc. Amer. Assoc. Cancer Res., 99:2607, 2008
111. Kaur P, Shukla S and **Gupta S**: Apigenin inactivates Akt to trigger apoptosis in human prostate cancer cells. Proc. Amer. Assoc. Cancer Res., 99:3072, 2008
112. Rabi T, Zhang A and **Gupta S**: Betulinic acid inhibits constitutive activation of NF-KB and induces apoptosis in human prostate cancer cells. Proc. Amer. Assoc. Cancer Res., 99:3831, 2008
113. Vykhovanets EV, Shukla S, MacLennan GT and **Gupta S**: Upregulation of chemoattractant signals causes leukocyte extravasation in IL-1 β -induced C57b/6j mice. Late Breaking Abstract-LB134 Proc. Amer. Assoc. Cancer Res., 99:38-39, 2008
114. Weis MC, Avva J, Mesarovic MD, Loparo KA, **Gupta S** and Sreenath SN: Complex systems biology of prostate cancer. Late Breaking Abstract-LB290 Proc. Amer. Assoc. Cancer Res., 99:79-80, 2008
115. Shukla S, Pandey M, MacLennan GT and **Gupta S**: Loss of maspin expression correlates with prostate cancer progression. Late Breaking Abstract-LB318 Proc. Amer. Assoc. Cancer Res., 99:88, 2008
116. Pandey M and **Gupta S**: Reactivation of epigenetically silenced glutathione-S-transferase-pi gene by green tea in prostate cancer. Research ShowCASE#376, CWRU, 2008
117. Shukla S, MacLennan GT and Gupta S: Forkhead transcription factor subfamily 'O' expression during prostate carcinogenesis. Research ShowCASE#377, CWRU, 2008
118. Shukla S, Pandey M, MacLennan GT and **Gupta S**: Loss of maspin expression contributes towards prostate cancer progression. Research ShowCASE#375, CWRU, 2008
119. Srivastava JK and **Gupta S**: Chamomile: Moving forward to develop as anticancer agent. Research ShowCASE#378, CWRU, 2008
120. Tao M, Boncher N, **Gupta S**, Penn M, Damaser M and Hijaz A: Effect of aging on the expression of stem cell homing chemokine expression in rat model of simulated birth trauma. Research ShowCASE#379, CWRU, 2008
121. Vykhovanets EV, Shukla S, MacLennan GT and **Gupta S**: Nuclear Factor-kappaB activation induces multitype behavior of intraprostatic chemoattractant receptors and leukocytes. Research ShowCASE#380, CWRU, 2008

122. Shukla S, MacLennan GT and **Gupta S**: Deregulation of FOXO3A contributes to prostate cancer progression. Proc. Amer. Urol. Asso. 179:460-461, 2008
123. Tao M, Boncher N, **Gupta S**, Penn M, Damaser M and Hijaz A: Effect of aging on the expression of stem cell homing chemokine expression in rat model of stimulated birth trauma. Proc. Amer. Urol. Asso. 179:471, 2008
124. Shukla S, Pandey M, MacLennan GT and **Gupta S**: Loss of maspin expression is a potential prognostic factor during prostate cancer progression. Proc. Amer. Urol. Asso. 179:229, 2008
125. Vykhovanets EV, Shukla S, MacLennan GT and **Gupta S**: Chemoattractant signals provide relationship between Nuclear Factor- κ B and intraprostatic inflammation. Proc. Amer. Urol. Asso. 179:34, 2008
126. Srivastava JK, Shukla S, Kamel C, MacLennan GT, Seftel A, and **Gupta S**: Finasteride induces oxidative stress in the Sprague-Dawley rats. 84th Annual Western Section AUA Annual Meeting, Monterey, California, October 26-30, 2008
127. **Shukla S, Shukla M, Abbas A, MacLennan GT, Fu P and **Gupta S**: Role of FOXO family members during prostate cancer progression. 18th Annual Fall Meeting of Society for Basic Urologic Research (SBUR), November 21, 2008
128. Pandey M and **Gupta S**: Molecular mechanisms of GSTP1 reactivation by green tea polyphenols in LNCaP cells. 6th Annual NHP Research Conference, Vancouver, BC February 18-21, 2009
129. **Shukla S and **Gupta S**: Apigenin-induced prostate cancer cell death is initiated by histone deacetylase inhibition, reactive oxygen species generation and p53 activation. International Conference on Advances in Free Radical Research & 8th Annual meeting of the Society for Free Radical Research, Lucknow, India, March 19-21, 2009
130. Srivastava JK, Shukla S and **Gupta S**: Suppression of NF- κ B and NF- κ B-regulated gene expression by chamomile in human prostate cancer PC-3 cells. Research ShowCASE#390, CWRU, 2009
131. Nawab A and **Gupta S**: Anticancer properties of some tropical Indian plants. Research ShowCASE#391, CWRU, 2009
132. Shukla S and **Gupta S**: Apigenin targets X-linked inhibitor of apoptosis (XIAP) through HDAC1 suppression. Research ShowCASE#188, CWRU, 2009
133. Vykhovanets EV, MacLennan GT, Vykhovanets O, and **Gupta S**: Accumulation of interleukin-17 cells in prostate inflammatory atrophy lesions of patients with prostate cancer. Research ShowCASE#189, CWRU, 2009
134. Abbas A, Shukla S, Umar S, MacLennan GT and **Gupta S**: Role of histone deacetylase (HDAC1) and histone acetyltransferase (CBP/p300) in pathogenesis of prostate cancer. Proc. Amer. Assoc. Cancer Res. 100:1328, 2009
135. Srivastava JK and **Gupta S**: Pharmacokinetics and safety evaluation of chamomile. Proc. Amer. Assoc. Cancer Res. 100:926, 2009
136. Shukla S and **Gupta S**: Apigenin downregulates XIAP protein expression through HDAC1 in prostate cancer. Proc. Amer. Assoc. Cancer Res. 100:2962, 2009
137. Srivastava JK, Shukla S and **Gupta S**: Chamomile suppresses constitutive and TNF α -induced NF- κ B activation in human prostate carcinoma PC-3 cells. Proc. Amer. Assoc. Cancer Res. 100:2969, 2009
138. Pandey M, Abbas A, Kaur P, Shukla S, **Gupta S**: Inhibition of histone deacetylase by plant flavone apigenin: A novel mechanism of chemoprotection. Proc. Amer. Assoc. Cancer Res. 100:2990, 2009
139. Shukla S, Shukla M, Abbas A, MacLennan GT, Fu P and **Gupta S**: Deregulation of FOXO factors in prostate cancer. Proc. Amer. Assoc. Cancer Res. 100:3902, 2009
140. Shukla S, Srivastava JK, Vykhovanets EV, Singh R, Flask CA, MacLennan GT and **Gupta S**: High-fat diet causes immune suppression and increased inflammation in MPAKT mice. Proc. Amer. Urol. Asso. 181:46, 2009

141. Srivastava JK, Shukla S, Kamel C, MacLennan GT, Seftel AD and **Gupta S**: Finasteride induces hypoxia-inducible factor 1- α in the prostate of Sprague-Dawley rats. Proc. Amer. Urol. Asso. 181:95, 2009
142. Abbas A, Shukla S, Umar S, MacLennan GT and **Gupta S**: Histone deacetylase (HDAC1) and histone acetyltransferase (CBP/p300) in the pathogenesis of prostate cancer. Proc. Amer. Urol. Asso. 181:393, 2009
143. **Vykhovanets EV, MacLennan GT, Vykhovanets O and **Gupta S**: Nuclear Factor-kappaB provides mechanistic link between inflammation and prostate cancer. Amer. Asso. Immunol. Annual meeting, May 71-2, 2009 Seattle, WA, J Immunol 182:93-8, 2009
144. Bhaskaran N, Shukla S and **Gupta S**: Anti-inflammatory activity of chamomile (*Matricaria Chamomilla*) through the inhibition of inducible nitric oxide synthase (iNOS) expression and NO production. Research ShowCASE#303, CWRU, April 15, 2010
145. Sharma HP and **Gupta S**: Apigenin absorption and sub-cellular distribution in human prostate cancer cells. Research ShowCASE#304, CWRU, April 15, 2010
146. Shukla S, MacLennan GT, Fu P and **Gupta S**: Special AT-Rich Sequence-Binding Protein 1 (SATB1) is a target for prostate cancer metastasis. Research ShowCASE#305, CWRU, April 15, 2010
147. Fnu R, Sharma HP and **Gupta S**: Relationship of oxidative DNA damage to GSTP1 gene methylation in prostate cancer. Research ShowCASE#306, CWRU, April 15, 2010
148. Nawab A and **Gupta S**: Differential growth inhibition, cell cycle deregulation and apoptotic response of *Solanum nigrum* in non-tumorigenic *versus* human prostate cancer cells. Research ShowCASE#307, CWRU, April 15, 2010
149. Shankar E, Vykhovanets YV, Vykhovanets OV and **Gupta S**: High-fat diet induced NF-kB activation: A cause for prostate inflammation and cancer pathogenesis. Research ShowCASE#308, CWRU, April 15, 2010
150. Thakur VS, Gupta K and **Gupta S**: Green tea polyphenols upregulate GSTP1 activity by increasing total and acetylated p53. Research ShowCASE#309, CWRU, April 15, 2010
151. Vykhovanets YV, MacLennan GT, Vykhovanets OV and **Gupta S**: IL-17 expressed CD68+ tissue macrophages and neutrophils present a mechanistic link between chronic inflammation and prostate cancer. Research ShowCASE#310, CWRU, April 15, 2010
152. Thakur VS, Gupta K and **Gupta S**: p53 acetylation by green tea polyphenols leads to upregulation of GSTP1 activity. Proc. Amer. Assoc. Cancer Res. 101:3801, 2010
153. Fnu R, Sharma HP and **Gupta S**: Oxidative DNA damage and its relationship with GSTP1 methylation in prostate cancer. Proc. Amer. Assoc. Cancer Res. 101:4903, 2010
154. Nawab A and **Gupta S**: Screening of some tropical Indian plants for their anticancer activity. Proc. Amer. Assoc. Cancer Res. 101:5714, 2010
155. Shukla S, MacLennan GT, Fu P and **Gupta S**: Overexpression of SATB1 (Special AT-Rich Sequence-Binding Protein 1) in prostate cancer potentiates metastatic phenotype. Proc. Amer. Assoc. Cancer Res. 101:2364, 2010
156. Shukla S and **Gupta S**: Transcriptional repression of androgen receptor in human prostate cancer cells by plant flavone apigenin. Proc. Amer. Assoc. Cancer Res. 101:3804, 2010
157. Bhaskaran N, Shukla S and **Gupta S**: Induction of phase 2 antioxidant genes by the aqueous extract of *Matricaria chamomilla* (Chamomile) through Keap1-Nrf2 signaling pathway. Proc. Amer. Assoc. Cancer Res. 101:1899, 2010
158. **Vykhovanets YV, Vykhovanets OV, Ponsky LE, Cherullo EE and **Gupta S**: Nuclear factor-kappaB is a therapeutic target in cystitis. J. Immunol. 183: 131.2010 (Abstr)

159. Vykhovanets YV, Vykhovanets OV, Shankar E and **Gupta S**: High fat diet induces intraprostatic nuclear factor kappaB activity and up-regulates levels of T regulatory cells. Proc. Amer. Urol. Asso. 182:678, 2010
160. **Vykhovanets YV, MacLennan GT, Vykhovanets OV and **Gupta S**: IL-17 expressed leukocytes are characteristic of prostate inflammatory atrophy lesions in patients with prostate cancer. Proc. Amer. Urol. Asso. 182:804, 2010
161. **Shukla S and **Gupta S**: Forkhead Transcription factor 'O' mediates prostate cancer progression in transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 2010 Fall Symposium of Society for basic Urologic Research (SBUR), November 12, 2010
162. Gupta K, Babcook MA, Thakur VS, Nawab A, Jackson MW, **Gupta S**: p53-dependent and p53-independent responses by green tea polyphenols in human prostate cancer cells. Proc. Amer. Assoc. Cancer Res. 102: 5570, 2011
163. Shankar E, Vykhovanets EV, Vykhovanets OV, Bhaskaran N, Shukla S, **Gupta S**: High fat diet-induced intraprostatic inflammation involves association between Stat-3 and NF-kappaB: Role in pathogenesis of prostate cancer. Proc. Amer. Assoc. Cancer Res. 102: 2164, 2011
164. Gupta K, Thakur VS, Bhaskaran N, **Gupta S**: Green tea polyphenols inhibit histone deacetylases and modulate p53 transcriptional activities in human prostate cancer cells. Proc. Amer. Assoc. Cancer Res. 102: 5584, 2011
165. Thakur VS, Gupta K, **Gupta S**: Green tea polyphenols causes cell cycle arrest and apoptosis of prostate cancer cells by suppressing class I histone deacetylases. Proc. Amer. Assoc. Cancer Res. 102: 4600, 2011
166. Kanwal R, Sharma H, **Gupta S**: Plant flavonoid apigenin preferentially binds with GC-rich DNA sequences and inhibits DNA methylation. Proc. Amer. Assoc. Cancer Res. 102: 3683, 2011
167. Shukla S, Bhaskaran N, **Gupta S**: Rhamnetin inhibits human prostate cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators and survival molecules. Proc. Amer. Assoc. Cancer Res. 102: 5576, 2011
168. Bhaskaran N, Shukla S, **Gupta S**: Chamomile confers protection against hydrogen peroxide-induced toxicity through activation of Nrf2-mediated defense response. Proc. Amer. Assoc. Cancer Res. 102: 4626, 2011
169. Shukla S, **Gupta S**: Apigenin intake suppresses IGF-I signaling in an autochthonous mouse model of prostate cancer. Proc. Amer. Assoc. Cancer Res. 102: 4599, 2011
170. Sharma H, **Gupta S**: Sub-cellular distribution and antioxidant potential of plant flavonoid apigenin. Proc. Amer. Assoc. Cancer Res. 102: 4632, 2011
171. Shankar S, Vykhovanets EV, Vykhovanets OV, Shukla S, **Gupta S**: High fat diet induces intraprostatic association of Stat-3 and NF-KB in the nucleus: A cause for prostate inflammation. Proc. Amer. Urol. Asso. 183:827, 2011
172. Babcook MA, Datt M, **Gupta S**: Molecular modeling predicts high-affinity binding of green tea catechin gallates to HMG-CoA reductase catalytic active site. CCCC Retreat, #45, July 8-9, 2011
173. Bhaskaran N, Shukla S, **Gupta S**: Chamomile protects against hydrogen peroxide-induced cellular toxicity through activation of Nrf2-mediated antioxidant defense. CCCC Retreat, #11, July 8-9, 2011
174. Kanwal R and **Gupta S**: Apigenin binds with GC rich promoter sequence and inhibits DNA methylation. CCCC Retreat, #3, July 8-9, 2011
175. Shukla S and Gupta S: Apigenin modulates IGF-I signaling in transgenic adenocarcinoma of the mouse prostate (TRAMP) model. CCCC Retreat, #4, July 8-9, 2011
176. Thakur VS, Gupta K, **Gupta S**: Downregulation of class-I histone deacetylases by green tea polyphenols in prostate cancer cells lead to increased expression of p21 and bax, causing cell cycle arrest and apoptosis. CCCC Retreat, #18, July 8-9, 2011

177. **Shankar E, Vykhovanets EV, Vykhovanets OV, MacLennan GT, Singh R, Bhaskaran N, Shukla S, Daneshgari F, **Gupta S**: High-fat diet consumption initiates intraprostatic inflammation in response to the association of NF- κ B and Stat-3. Urology Program Director's Meeting, Poster#10, Nov 30-Dec 2, 2012
178. Bhaskaran N, Shukla S, Gupta S: Chamomile (*Matricaria chamomilla* L.) upregulates heme oxygenase-1 through activation of ERK-Nrf2 signaling: Cytoprotective mechanism against oxidative damage. Proc. Amer. Assoc. Cancer Res. 103: 2594, 2012
179. Shukla S, Bhaskaran N, MacLennan GT, Fu P, **Gupta S**: Apigenin intake regulates Fox 'O' signaling in an autochthonous mouse model of prostate cancer. Proc. Amer. Assoc. Cancer Res. 103: 617, 2012
180. Kanwal R, Fu P, **Gupta S**: Increased oxidative DNA damage in human prostate cancer and its relationship to GSTP1 expression. Proc. Amer. Assoc. Cancer Res. 103: 614, 2012
181. Thakur VS, Gupta K, Gupta S: Green tea polyphenols cause stabilization and increased transcriptional activity of p53 by increasing its acetylation through inhibition of class I histone deacetylases. Proc. Amer. Assoc. Cancer Res. 103: 2583, 2012
182. Bhaskaran N, Shukla S, Ponsky LE, Cherullo EE, **Gupta S**: Lyc-O-Mato causes cell cycle arrest and apoptosis in human bladder transitional carcinoma cells. Proc. Amer. Assoc. Cancer Res. 103: 2569, 2012
183. Cooney MM, Thompson CL, Lin P-Y, Cheng K-L, McGuffin-Cawley JD, Shieu F-S, Samia AC, **Gupta S**, Liu C-C: Detection of alpha-methylacyl-CoA racemase (AMACR), a biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor. Amer. Soc. Clin. Oncol. Abs#103586, McCormick Place, Chicago, Illinois, June 1-5, 2012
184. Shukla S, Srivastava JK, Kanwal R, Nawab A, Sharma H, Bhaskaran N, Lillibridge C, Ponsky LE, Fu P, MacLennan GT, **Gupta S**: Oxidative stress and antioxidant status in high-risk prostate cancer subjects. Proc. Amer. Assoc. Cancer Res. 104: 9, 2013
185. Babcook MA, Sramkoski RM, Vazquez EJ, Puchowicz MA, Shukla S, **Gupta S**: Synergistic simvastatin and metformin chemotherapy for metastatic castration-resistant prostate cancer. Proc. Amer. Assoc. Cancer Res. 104: 3283, 2013
186. Shukla S, Datt M, Chance MR, **Gupta S**: Apigenin suppresses IKK activation and downstream signaling leading to prostate cancer inhibition. Proc. Amer. Assoc. Cancer Res. 104: 3660, 2013
187. Gupta K, Thakur VS, Bhaskaran N, Nawab A, Babcook MA, Jackson MW, **Gupta S**: Differential mechanisms of green tea polyphenols-induced apoptosis in human prostate cancer cells: Role of p53. Proc. Amer. Assoc. Cancer Res. 104: 3684, 2013
188. Bhaskaran N, Shukla S, Thakur VS, Babcook MA, MacLennan GT, Liu G, Daneshgari F, **Gupta S**: High-fat diet induces inflammation by increasing estrogen levels through Stat3, estrogen receptor alpha and aromatase in the mouse prostate. Proc. Amer. Assoc. Cancer Res. 104: 5452, 2013
189. Shukla S, Srivastava JK, Kanwal R, Nawab A, Sharma H, Bhaskaran N, Lillibridge C, Ponsky LE, Fu P, MacLennan GT, **Gupta S**: Increased oxidative stress and DNA damage in high-risk prostate cancer subjects. Proc. Amer. Urol. Asso. 185:2232, 2013
190. Bhaskaran N, Shukla S, Thakur VS, Babcook MA, MacLennan GT, Liu G, Daneshgari F, **Gupta S**: High-fat diet induced inflammation in the prostate: Role of Stat-3, ER-alpha and Aromatase. Proc. Amer. Urol. Asso. 185:1179, 2013
191. **Babcook MA, Shukla S, Fu P, Sramkoski RM, Vazquez EJ, Puchowicz MA, Lindner DJ, Parker Y, **Gupta S**: Synergistic simvastatin and metformin combination chemotherapy for metastatic castration-resistant prostate cancer. CCCC Retreat, #3, July 11-12, 2013
192. **Babcook MA, Sramkoski RM, Vazquez EJ, Puchowicz MA, Shukla S, **Gupta S**: Synergistic action of simvastatin and metformin on metastatic castration-resistant prostate cancer. Research ShowCASE, CWRU, April 12, 2013

193. Deb G, Thakur VS, Limaye AM, **Gupta S**: Epigenetic re-expression of TIMP-3 by green tea polyphenols in breast and prostate cancer. Research ShowCASE, CWRU, April 12, 2013
194. Shukla S, Datt M, Chance MR, **Gupta S**: Apigenin modulates IKK complex in inhibiting prostate cancer progression. Research ShowCASE, CWRU, April 12, 2013
195. ****Babcook MA, Sramkoski RM, Vazquez EJ, Puchowicz MA, Shukla S, Gupta S**: Synergistic simvastatin and metformin combination chemotherapy for metastatic castration-resistant prostate cancer. Biomedical Graduate Student Symposium, CWRU, May 2013
196. Babcook MA, Sramkoski RM, Oak CZ, **Gupta S**: Combination simvastatin and metformin induces cell death by autophagy and secondary necrosis in osseous metastatic castration-resistant prostate cancer cells. Proc. Amer. Assoc. Cancer Res. 105: 804, 2014
197. Oak CZ, Bhaskaran N, **Gupta S**, Shukla S: Antiproliferative, antioxidant and antiapoptotic effect of rhamnetin in human prostate cancer cells. Proc. Amer. Assoc. Cancer Res. 105: 1232, 2014
198. Deb G, Thakur VS, Limaye AM, **Gupta S**: Green tea polyphenol-mediated epigenetic reactivation of TIMP-3 reduces invasiveness and gelatinolytic activity in human breast cancer cells. Proc. Amer. Assoc. Cancer Res. 105: 253, 2014
199. Shukla S, Fu P, **Gupta S**: Apigenin suppresses inhibitor of apoptosis family protein expression and disrupts Ku70-bax interaction in prostate cancer cells in culture and in vivo. Proc. Amer. Assoc. Cancer Res. 105: 1238, 2014
200. Oak CZ, Bhaskaran N, **Gupta S**, Shukla S: Rhamnetin attenuates tumorigenesis by suppressing oxidative stress in human prostate cancer cells. Research ShowCASE#220, CWRU, April 11, 2014
201. Deb G, Thakur VS, Limaye AM, **Gupta S**: Reactivation of TIMP-3 by green tea polyphenols reduces invasiveness and gelatinolytic activity in human breast cancer cells. Research ShowCASE#317, CWRU, April 11, 2014
202. ****Babcook MA, Shukla S, Sramkoski RM, Fu P, Vazquez EJ, Puchowicz MA, Oak CZ, Molter JP, MacLennan GT, Daneshgari F, Gupta S**: Simvastatin and metformin: A deadly combination for metastatic castration-resistant prostate cancer. Research ShowCASE#236, CWRU, April 11, 2014
203. Kanwal R, Sharma HP, Bhaskaran N, **Gupta S**: Binding of apigenin to nucleic acid bases reduces oxidative DNA damage in prostate epithelial cells. Research ShowCASE#81, CWRU, April 11, 2014
204. Oak CZ, **Gupta S**, Shukla S: Differential effect of diosmetin on androgen-sensitive and androgen-refractory human prostate cancer cells. Research ShowCASE#502A, CWRU, April 11, 2014
205. Shukla S, Fu P, **Gupta S**: Suppression of inhibitor of apoptosis family proteins and disruption of Ku70-Bax interaction by apigenin causes apoptosis in prostate cancer cells. Research ShowCASE#82, CWRU, April 11, 2014
206. ****Babcook MA, Shukla S, Sramkoski RM, Fu P, Vazquez EJ, Puchowicz MA, Oak CZ, Molter JP, MacLennan GT, Daneshgari F, Gupta S**: Simvastatin and metformin: A deadly combination for metastatic castration-resistant prostate cancer. Proc. Amer. Urol. Asso. 191:PD27-06, Vol 4S, 2014
207. ****Shankar E, Pandey M, Candamo M, Lee A, Shukla S, Fu P, MacLennan GT, Gupta S**. Upregulation of maspin involves class I histone deacetylase inhibition and p53 activation in prostate cancer cells. Society of Basic Urology Research Fall Session, P109, November 14, 2015
208. Vykhovanets E, Shankar E, Shukla S, Vykhovanets O, MacLennan GT, **Gupta S**. NF- κ B as a prognostic marker and therapeutic target in prostate cancer. Proc. Amer. Assoc. Cancer Res. 106: 91, 2015
209. Babcook MA, Sramkoski RM, Fujioka H, Daneshgari F, Almasan A, Shukla S, **Gupta S**. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necroptosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Proc. Amer. Assoc. Cancer Res. 106: 16, 2015
210. Oak C, Bhaskaran N, **Gupta S**, Shukla S. Rhamnetin inhibits prostate cancer progression in an autochthonous mouse prostate cancer model. Proc. Amer. Assoc. Cancer Res. 106: 1913, 2015

211. Shukla S, Abbas A, **Gupta S**. Apigenin increases maspin expression and suppresses invasiveness in prostate cancer cells. *Proc. Amer. Assoc. Cancer Res.* 106: 4649, 2015
212. **He Q, Shukla S, Wang Z, Liu G, Erokwu B, Flask C, Lu L, Babcook MA, Daneshgari F, **Gupta S**. Obesity-induced metabolic syndrome promote lower urinary tract symptoms (LUTS) in a mouse model. *Proc. Amer. Urol. Asso.* 192: NOMCC: 228-230, 2015
213. Vykhovanets E, Shukla S, Shankar E, Vykhovanets O, MacLennan GT, **Gupta S**. Real time in vivo molecular imaging of NF-kappaB in prostate cancer: Role as prognostic biomarker and therapeutic target. *Proc. Amer. Urol. Asso.* 192: NOMCC: 225-227, 2015
214. Babcook MA, Sramkoski RM, Fujioka H, Daneshgari F, Almasan A, Shukla S, **Gupta S**. Synergistic combination of simvastatin and metformin induces necroptosis in metastatic castration-resistant prostate cancer cells. *Research ShowCASE, CWRU*, April 17, 2015
215. Vykhovanets E, Shukla S, Shankar E, Vykhovanets O, MacLennan GT, **Gupta S**. NF-kB: A critical prognostic marker and therapeutic target in prostate cancer. *Research ShowCASE, CWRU*, April 17, 2015
216. Shukla S, Shankar S, **Gupta S**. Effects of plant flavone apigenin on maspin gene expression in human prostate cancer cells. *Research ShowCASE, CWRU*, April 17, 2015
217. He Q, Shukla S, Wang Z, Liu G, Erokwu B, Flask C, Lu L, Babcook MA, Daneshgari F, **Gupta S**. Novel mouse model of lower urinary tract symptom. *Research ShowCASE, CWRU*, April 17, 2015
218. Vykhovanets E, Shukla S, Shankar E, Vykhovanets O, MacLennan GT, **Gupta S**. NF-kB an emerging target in prostate cancer. *Case Comprehensive Cancer Center Retreat July 9-10, 2015*
219. Shankar E, Candamo M, Shukla S, **Gupta S**. Apigenin enhances maspin expression and decreases invasiveness in human prostate cancer cells. *Case Comprehensive Cancer Center Retreat July 9-10, 2015*
220. **Shankar E, Pandey M, Candamo M, Lee A, Shukla S, Fu P, MacLennan GT, **Gupta S**. Upregulation of maspin involves class I histone deacetylase inhibition and p53 activation in prostate cancer cells. *Society of Basic Urology Research Fall Session, P109, November 14, 2015*
221. Ebron JS, Singh J, Sikand K, Shankar E, **Gupta S**, Shukla GC. Tumor suppressing dual-action miRNA: Targeting Warburg effect and androgen receptor function in CRPC. *Proc. Amer. Assoc. Cancer Res.* 107: 1119, 2016
222. Deb G, Thakur VS, Shankar E, **Gupta S**. Epigenetic reactivation of TIMP-3 in human prostate cancer cells by green tea polyphenols. *Proc. Amer. Assoc. Cancer Res.* 107: 2609, 2016
223. Babcook MA, Akgul M, Margevicius S, MacLennan GT, Fu P, Abouassaly R, **Gupta S**. A distinct AMP-activated protein kinase phosphorylation site is associated with metastasis and castration-resistance in prostate cancer. *Proc. Amer. Assoc. Cancer Res.* 107: 4963, 2016
224. Kanwal R, Datt M, **Gupta S**. Inhibition of DNA methyltransferases and histone methyltransferases by plant flavones. *Proc. Amer. Assoc. Cancer Res.* 107: 5258, 2016
225. **Babcook MA, Akgul M, Margevicius S, MacLennan GT, Fu P, Abouassaly R, **Gupta S**. Phosphorylation of AMPK α at Ser-485/491 is associated with metastasis and castration-resistance in prostate cancer: A clinical study. *Proc. Amer. Urol. Asso.* 193: SDCC: PD32-10, 2016
226. Estemalik J, Bissada N, Joshi N, Demko C, Shankar E, Bodner D, **Gupta S**. Possible link between periodontal disease and chronic prostatitis. *Proc. Amer. Urol. Asso.* 193: SDCC: PD20-05, 2016
227. **Shankar E, Kanwal R, Candamo M, Lee A, Pandey M, Thakur VS, Fu P, MacLennan GT, **Gupta S**. Class I HDAC inhibition and p53 activation upregulates maspin in human prostate cancer. *Proc. Amer. Urol. Asso.* 193: SDCC: MP62-09, 2016
228. Glover M, Soni S, Ren Q, MacLennan GT, Fu P, **Gupta S**. Expression of Bcl-2 and PCNA in prostate needle biopsy specimens. *Research ShowCASE, CWRU*, April 15, 2016

229. Kanwal R, Datt M, **Gupta S**. Plant flavones as dual inhibitors of DNA methyltransferases and histone methyltransferases. Research ShowCASE, CWRU, April 15, 2016
230. Thakur VS, Deb G, Jackson MW, **Gupta S**. Green tea-mediated p53 acetylation upregulate glutathione S-transferase P1 in human prostate cancer cells. Research ShowCASE, CWRU, April 15, 2016
231. Candamo M, Shankar E, Kanwal R, Pandey M, Shukla S, Fu P, MacLennan GT, **Gupta S**. Upregulation of maspin involves class I HDAC inhibition and p53 activation in prostate cancer cells. Second Annual Cancer Research Fair, Thwing Ballroom, CWRU, 2016
232. Deb G, Thakur VS, Shankar E, **Gupta S**. Green tea polyphenols-mediated epigenetic induction of TIMP-3 delays migration and invasiveness in prostate cancer cells. Research ShowCASE, CWRU, April 15, 2016
233. Candamo M, Shankar E, Kanwal R, Pandey M, Shukla S, Fu P, MacLennan GT, **Gupta S**. Molecular mechanisms of cancer prevention by plant flavone apigenin. 33rd Association of Indian Physicians of Norther Ohio (AIPNO) Research Showcase, 2016
234. Zhu M, Chen W, Glover M, Shankar E, **Gupta S**, MacLennan GT. Heterogeneity of neuroendocrine differentiation in whole-mount radical prostatectomy specimens. Abstract#5783 United States & Canadian Academy of Pathology (USCAP) Meeting, 2017
235. Estemalik J, Bissada N, Joshi N, Demko C, Shankar E, Bodner D, **Gupta S**. Similar pathogens in EPS of patients with periodontitis and prostatitis. American Association for Dental Research (AADR), 2017
236. Shankar E, Kanwal R, Goel A, Yang X, Shukla S, MacLennan GT, Fu P, Madabhushi A, Ramakrishnan P, **Gupta S**. Targeting the PI3K-Akt and NF- κ B pathways as a combination therapy in blocking prostate cancer progression. Abstract#1080: Proc. Amer Asso. Cancer Res. 2017
237. Shankar E, Bhaskaran N, Kanwal R, **Gupta S**. Green tea polyphenols suppress tumor growth and invasion by targeting matrix metalloproteinases, RECK and TIMP-3, in a mouse model implanted with prostate tumors. Abstract#2225: Proc. Amer Asso. Cancer Res. 2017
238. Kanwal R, Yang X, Shankar E, **Gupta S**. Luteolin selectively inhibits EZH2 and blocks H3K27 methylation in prostate cancer cells. Abstract#2230: Proc. Amer Asso. Cancer Res. 2017
239. Soni S, Glover M, Ren Q, MacLennan GT, Fu P, **Gupta S**. Chronic inflammation contributes to neoplastic progression in prostate tissue: a needle biopsy study. Abstract#492: Proc. Amer Asso. Cancer Res. 2017
240. Zhu M, Chen W, Glover M, Shankar E, MacLennan GT, **Gupta S**. Prognostic role of neuroendocrine differentiation marker in prostate adenocarcinoma. Abstract LB-255, Proc. Amer Asso. Cancer Res. 2017
241. Leo P, Janaki N, Thawani R, Elliott R, **Gupta S**, Shih N, Feldman MD, Madabhushi A. Computer extracted features of gland morphology on H&E surgically resected tissue images as predictive of biochemical recurrence and rate of expression in African American compared to Caucasian American men. Abstract#188376 J Clin Oncol 35, 2017 (suppl; abstr e16559) ASCO Annual Meeting, 2017
242. Zhu M, Chen W, Glover M, **Gupta S**, MacLennan GT. Evaluating Heterogeneity of neuroendocrine differentiation of prostate adenocarcinoma in Radical Prostatectomy Specimen. Proc. Amer. Urol. Asso. 194, 2017
243. Kanwal R, Yang X, Shankar E, **Gupta S**. Luteolin is a selective inhibitor of EZH2 and blocks H3K27 methylation in prostate cancer cells. Research ShowCASE, CWRU, 2017
244. **Goel A, Shankar E, Yang X, **Gupta S**. Synergistic combination of Inhibitor VIII and Parthenolide inhibits human prostate cancer through Akt and NF- κ B signaling in vitro and in vivo. Research ShowCASE, CWRU, 2017
245. Franco D, Shankar E, Zhang A, **Gupta S**. Betulinic acid mediates apoptosis by suppressing NF- κ B and activating p53 in human prostate cancer cells. Research ShowCASE, CWRU, 2017

246. Zhu M, Chen W, Glover M, Shankar E, MacLennan GT, **Gupta S**. Evaluating neuroendocrine differentiation and its clinical significance in Radical Prostatectomy Specimen. Research ShowCASE, CWRU, 2017
247. Ali M, Janaki N, Franco D, Shankar E, MacLennan GT, **Gupta S**. Androgen deprivation therapy enhances cancer stem cell population in prostate tumors. Research ShowCASE, CWRU, 2017
248. Shankar E, Bhaskaran N, Kanwal R, **Gupta S**. Epigenetic reactivation of TIMP-3 and RECK by green tea polyphenols inhibits prostate cancer invasiveness. Research ShowCASE, CWRU, 2017
249. Soni S, Glover M, Ren Q, MacLennan GT, Fu P, **Gupta S**. Relationship between chronic inflammation and neoplastic progression in prostate tissue. Research ShowCASE, CWRU, 2017
250. El-Hayek V, Shankar E, Yang X, **Gupta S**. Synergistic treatment targeting EZH2 and androgen receptor in castrate resistant prostate cancer. Research ShowCASE, CWRU, 2017
251. Zhu M, Chen W, Gupta S, MacLennan GT. Heterogeneity of neuroendocrine differentiation in prostate adenocarcinoma: A study on whole-mount radical prostatectomy specimens. Abstract#1091, 106 Annual Meeting USCAP, San Antonio, TX, March 4-10, 2017
252. Ren Q, Glover M, Soni S, MacLennan GT, Gupta S. Influence of chronic inflammation on Bcl2 and PCNA expression in prostate needle biopsy specimens. Abstract#1016, 106 Annual Meeting USCAP, San Antonio, TX, March 4-10, 2017
253. Shankar E, Kanwal R, Goel A, Yang X, Shukla S, MacLennan GT, Fu P, Li J, Madabhushi A, **Gupta S**. Prostate cancer aggressiveness is mediated by Akt and NF- κ B signaling pathways: A system biology approach. J. Urol. Vol. 197, No. 4S, Supplement, e594, 2017
254. **Shankar E, Franco D, Iqbal O, Moreton S, Kanwal R, **Gupta S**. Combined targeting of EZH2 and androgen receptor in castration-resistant prostate cancer cells. SBUR Fall Meeting, Tampa, FL November 9-12, 2017
255. Glover M, Zhu M, Chen W, **Gupta S**, MacLennan GT. Prognostic significance of neuroendocrine differentiation markers in prostate cancer. Case Comprehensive Cancer Center Retreat poster presentation, 2017
256. **Shankar E, Kanwal R, Goel A, Yang X, Shukla S, MacLennan GT, Fu P, Li J, Madabhushi A, **Gupta S**. Interaction between signaling pathways in malignant prostate cancer: Understanding via mathematical modeling. 34th Association of Indian Physicians of Norther Ohio (AIPNO) Research Showcase, 2017
257. Franco D, Ali M, Janaki N, Shankar E, MacLennan GT, **Gupta S**. Enrichment of cancer stem cells during androgen deprivation therapy for prostate cancer. 34th Association of Indian Physicians of Norther Ohio (AIPNO) Research Showcase, 2017
258. **Glover M, Zhu M, Chen W, MacLennan GT, **Gupta S**. Neuroendocrine differentiation is a relevant prognostic factor in prostate cancer. 34th Association of Indian Physicians of Norther Ohio (AIPNO) Research Showcase, 2017
259. Soni S, Glover M, Ren Q, MacLennan GT, Fu P, **Gupta S**. Relationship between chronic inflammation and neoplastic progression in prostate tissue: A closer link. 34th Association of Indian Physicians of Norther Ohio (AIPNO) Research Showcase, 2017
260. **Leo P, Shankar E, Elliott R, Janowczyk A, **Gupta S**, Madabhushi A. Combination of nuclear NF- κ B/p65 localization and gland morphological features from surgical specimens appears to be predictive of early biochemical recurrence in prostate cancer patients. The International Society for Optics and Photonics (SPIE) Medical Imaging, 2018
261. Chen W, Jia L, **Gupta S**, MacLennan GT. Further evidence supporting the role of chronic inflammation in prostate carcinogenesis. USCAP Annual Meeting, Vancouver, BC, Canada, March 17-23, 2018
262. Bhargava HK, Leo P, Elliott R, Janowczyk A, Whitney J, **Gupta S**, Yamoah K, Rebbeck T, Feldman MD, Lal P, Madabhushi A. Computer-extracted stromal features of African-Americans versus Caucasians

from H&E slides and impact on prognosis of biochemical recurrence. Clin Oncol 36, 2018 (suppl; abstr 12075) ASCO Annual Meeting, 2018

263. Leo P, Shankar E, Elliott R, Janowczyk A, Janaki N, MacLennan GT, Madabhushi A, **Gupta S**. Combination of quantitative histomorphometry with NFκB/p65 nuclear localization is better predictor of biochemical recurrence in prostate cancer patients. LBPO.BSB01 - Late-Breaking Research: Bioinformatics and Systems Biology, Annual AACR Meeting, Chicago, IL, 2018
264. Kanwal R, Moreton S, Franco D, **Gupta S**. Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2. PO.PR01.01 - Chemoprevention of Cancer. Annual AACR Meeting, Chicago, IL, 2018
265. Kanwal R, Shukla S, Exner AA, Tzakos AG, **Gupta S**. Apigenin nanoparticle suppresses sphere formation in CD133+/ALDH1high prostate cancer stem cells through downregulation of stem cell markers. PO.PR01.01 - Chemoprevention of Cancer. Annual AACR Meeting, Chicago, IL, 2018
266. Shankar E, Franco D, Iqbal O, Moreton S, Kanwal R, **Gupta S**. Efficacy and toxicity of combinatorial therapy with EZH2 and androgen receptor inhibitor for castration-resistant prostate cancer. PO.ET01.03 - Combination Chemotherapy 1 Annual AACR Meeting, Chicago, IL, 2018
267. Leo P, Gawlik A, Zhu G, Feldman M, **Gupta S**, Veltri RW, Madabhushi A. Computer-extracted features of nuclear and glandular morphology from digital H&E tissue images predict prostate cancer biochemical recurrence and metastasis following radical prostatectomy. American Urologic Association (AUA), Volume 199, Issue 4, Supplement, Pages e446–e447, 2018
268. Leo P, Shankar E, Elliott R, Janowczyk A, Madabhushi A, **Gupta S**. Combination of nuclear NF-κB/p65 localization and gland morphological features from surgical specimens appears to be predictive of early biochemical recurrence in prostate cancer patients. American Urologic Association (AUA), Volume 199, Issue 4, Supplement, Page e450, 2018
269. Verma S, Shukla S, Pandey M, MacLennan GT, **Gupta S**. Differentially expressed genes and molecular pathways in an au-tochthonous mouse prostate cancer model. Abstract#4347 Annual AACR Meeting, Atlanta, GA, 2019
270. **Shankar E, Iqbal O, Bhaskaran N, Deb G, MacLennan GT, Fu P, **Gupta S**. Epigenetic modifications involving reactivation of RECK inhibit-ing MMP-9 and MMP-2 in prostate cancer. Abstract#5084 Annual AACR Meeting, Atlanta, GA, 2019

RESEARCH SUPPORT ONGOING

DoD PCRP W81XWH-18-1-0618 (Gupta, PI)

08/01/2018-07/30/2021

Targeting metabolic pathways in metastatic castrate-resistant prostate cancer

The major goal of this proposal is to test the efficacy and develop a combination of simvastatin and metformin as a safe, efficacious, and cost-effective agents to treat androgen signaling inhibitor resistant CRPC.

Direct cost: \$620,000.00 (3 years)

DoD PCRP PC180329 (Gupta, PI)

08/01/2019-07/30/2022

Prognostic Prediction Model for Prostate Cancer in African American Men

The major goal of this application is to address aspect of health disparity in prostate cancer by constructing a race-specific prostate cancer classifier for prognostic prediction and risk assessment.

Direct cost: 1,000,000.00 (Funds will expire for use on 09/30/2024)

Status: Recommended for funding (3 years)

NIH/NCI R01CA202814-01A1 (Steinmetz PI, Gupta Co-PI)

02/01/2016-01/31/2021

Diagnosis and longitudinal monitoring of metastatic prostate cancer through molecular MR imaging

The major goal of this proposal is to develop CD151free-targeted, shape-optimized contrast agent with high MR signal enhancement will provide sensitive delineation of CD151free expression in primary lesions and occult metastases.

Direct cost: \$1,312,695.00 (5 years)

I01BX002494-01A1 (Gupta, PI)

09/01/2015-08/31/2020

VA Merit Award

Targeting EZH2 in Prostate Cancer by Luteolin

The major goal of this proposal is to investigate the molecular mechanisms of prostate cancer suppression by luteolin, a common dietary plant flavonoid by targeting EZH2 in various prostate carcinoma cells and mouse models of prostate cancer.

Direct cost: \$1,048,000.00 (Under no cost extension)

W81XWH-15-1-0558 PC140311 DoD Idea Award (Gupta, PI)

09/01/2015-08/31/2018

Fused Biomarker-based Prediction of Aggressive from Indolent Prostate Cancer

The major goal of this application is to differentiate between indolent versus aggressive disease and predict the recurrence of prostate cancer by utilizing a novel suite of computerized image analysis and computer vision tools to quantify histomorphometric features of tumor along with the expression of two biomarkers which have a role in disease invasion and metastasis.

Direct cost: \$353,600.00 (Under no cost extension)

PENDING

R01 CA239446-01A1 (MPI Grant Madabhushi PI; Gupta, PI)

07/01/2019-06/30/2014

The goal of this project is to develop and validate an "integrated risk score" (IRiS) predictor using histomorphometric and selected molecular and histochemical biomarker measurements of the tumor and its habitat from surgically excised tissue specimens that is both prognostic of prostate cancer outcome and predictive of added benefit of chemotherapy following surgery.

Direct cost: 2,736,303.00

Status: 12 Percentile (Under negotiation)

I01 BX0000001 (Gupta, PI)

10/01/2019-09/30/2023

Role of IL-17 in BPH and LUTS Pathogenesis

The goal of the proposal is to understand the mechanistic basis of obesity-mediated IL-17 production in causing benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS).

Direct cost: 1,105,763.00

COMPLETED

NIH/NCI R21 CA193080-01 (Gupta, PI)

04/01/2015-03/31/2018

TIMP3: A Molecular Target of Green Tea Polyphenols

The major goal of this application was to understand the molecular mechanisms through which green tea polyphenols reactivate epigenetically silenced gene, TIMP3 in prostate cancer.

NIH/NCI R21 EB020946-01 (Steinmetz PI, Gupta Co-I)

07/01/2015-06/30/2017

Detection of lethal prostate cancer with macromolecule-based, EGFL-7 targeted MR imaging approach

The major goals of this proposal was to optimize the shape and surface chemistry of the contrast agent to achieve high sensitivity and spatial resolution during MRI imaging.

NIH/NCI R03CA186179-01A1 (Gupta, PI)

08/01/2014-07/31/2017

Prevention of Metastasis by Green Tea Polyphenols

The major goal of this application was to understand the molecular mechanisms through which green tea polyphenols suppresses prostate cancer metastasis.

NIH/NCI 2R01 CA108512-06 (Gupta PI)

09/01/2004-04/30/2016

Molecular Mechanisms of Prostate Cancer Chemoprevention by Apigenin

The major goal of this proposal was to investigate the molecular mechanisms of prostate cancer chemoprevention by apigenin, a common dietary plant flavonoid by targeting NF- κ B/IKK signaling pathway in various prostate carcinoma cells and mouse models of prostate cancer.

CTSC Core Utilization Award (Gupta, PI) 07/01/2015-06/30/2016
Correlation of AMP-activated protein kinase phosphorylation status, activity and protein expression with prostate cancer progression to castrate-resistance and metastasis in human archived specimens.
The goal of this proposal was to determine the expression pattern of AMP kinase during prostate cancer progression to metastatic castrate-resistant prostate cancer.

NCI/NIH RO1 CA115491-01 (Gupta, PI) 07/01/2007-06/30/2014
Molecular Mechanisms of GSTP1 Activation by Green Tea Polyphenols
The major goal of this proposal was to investigate the molecular mechanism(s) of green tea polyphenols in reactivating epigenetically silenced GSTP1 gene in prostate cancer cells and in tumor xenograft model of prostate cancer.

The Gateway for Cancer Research (Gupta, PI) 08/01/2013-07/31/2017
Randomized Study of Sunphenon Decaffeinated Capsules in Men with Low-Risk Prostate Cancer on Active Surveillance
The major goal of this clinical proposal was to test the efficacy of green tea polyphenols in inhibiting cancer progression in low-grade, low-volume prostate cancer patients on active surveillance.

T32 DK091213-01A1 (Daneshgari, Director and Gupta, Co-Director) 06/01/2012-05/31/2017
Case Urology Translational Research Training Program (CUTRTP)
The overarching goal of CUTRUP was to provide training to the new generation of scientists and surgeon-scientists. Establishment of the CWRU Urology Translational Research Training Program (CUTRTP) will expand the support for the training of postdoctoral PhD or postgraduate MDs in two tracks of scientists (for Ph.D. or M.D. candidates) and surgeon-scientists (for MD Candidates).

NIH/NCI RO3 CA166231-A1 (Shukla, PI and Gupta, Co-PI) 09/03/2012-08/31/2015
Effect of Rhamnetin on Oxidative Stress and Prostate Cancer
The major goal of this proposal was to investigate the effect of rhamnetin, a natural plant product in oxidative stress and prostate cancer using cell culture and *in vivo* model.

NIH/NCI R03 CA186179-01A1 (Gupta, PI) 09/01/2014-08/31/2017
Prevention of Metastasis by Green Tea Polyphenols
The major goal of this application was to understand the molecular mechanisms through which green tea polyphenols suppresses prostate cancer metastasis.

NIDDK P20 DK090871-01 (Daneshgari, PI and Gupta, Co-PI) 09/30/2010-08/31/2012
Urological Complications of Obesity and Diabetes (UCOD)
The major goal of this proposal was to encourage interdisciplinary studies on the Urologic Complications of Obesity and Diabetes (UCOD) including characterization of diabetic bladder dysfunction (DBD), prostate growth, and identification of molecular targets at the proteome level in the rodent models.

CTSC Core Utilization Award (Gupta, PI) 07/01/2013-06/30/2014
Effect of synergistic simvastatin and metformin chemotherapy in a mouse model of metastatic castrate-resistant prostate cancer.
The goal of this proposal was to determine the synergistic effect of two clinically approved drugs on mouse model of metastatic castrate-resistant prostate cancer.

NIH/NCI RO3 CA137667-01 (Shukla, PI and Gupta Co-PI) 07/16/2009-06/30/2012
FOXO: A Target for Prostate Cancer Prevention
The major goal of this proposal was to investigate the role of FOX "O" protein in pre-clinical models of prostate cancer.

ACS-Joseph S Silber Fellowship
IKK in Constitutive Activation of NF- κ B in Bladder Carcinoma Cells
Role: Advisor

07/01/2011-08/31/2011

NCCAM/NCI RO1 AT002709-01 (Gupta, PI) 09/15/2005-08/31/2011

Chamomile as Complementary and Alternative Medicine for Prostate Cancer

The major goal of this proposal was to investigate the molecular mechanism(s) of chamomile tea in the prevention of prostate cancer in cell culture and pre-clinical models of prostate cancer.

Sullivan Foundation for the Study and Cure of Prostatitis (Gupta, PI/Manager) 06/01/2001-05/31/2011

The purpose of this project is to use a commercially available prostate expression array to screen the sera of individuals with prostatitis to determine if they contain antibodies to prostatic proteins. Normal men, men with prostate cancer, and men with BPH will serve as controls. The reactive protein(s) will be cloned, sequenced & identified.

Type: Endowment grant

Presidential Research Initiative 2007/Case (Gupta, PI) 07/01/2007-06/30/2010

Prognostic Significance of NF- κ B and Akt in Prostate Cancer-A Systems Biology Approach

The purpose of this project was to develop a quantitative systems biology model by utilizing two complex signaling pathway subsystems for prognostic significance of prostate cancer.

Case Comprehensive Cancer Center (Gupta, PI) 01/01/2006-12/31/2008

Phase II, Randomized, Double-blind, Placebo-controlled Pilot Study of Polyphenon E in Men with Localized Prostate Cancer Scheduled to Undergo Radical Prostatectomy.

The major goal of this proposal was to evaluate the short-term effects of daily Polyphenon E administration during the interval between prostate biopsy and radical prostatectomy in men with localized prostate cancer.

NCI/NCCAM R21 CA109424-01 (Gupta, PI) 07/07/2004-06/30/2007

Reactivation of GSTP1 Gene by Green Tea Polyphenols

The major goal of this proposal was to investigate the potential of green tea polyphenols in reactivation of GSTP1 gene silenced in prostate carcinoma cells.

NIH RO3 CA107806-01 (Gupta, PI) 05/01/2004-04/30/2007

Anti-proliferative Effects of D-Limonene against Prostate Cancer

The major goal of this proposal was to investigate the anti-proliferative effects of D-limonene in human prostate carcinoma cells and transgenic mouse model of prostate cancer.

NCI/NCCAM R21 AT002258-01 (Haqqi, PI, Gupta, Co-PI) 04/01/2004-03/31/2007

Induction of Apoptosis in Osteosarcoma Cells by Green Tea

The major goal of this proposal was to investigate novel pathway which induces programmed cell death in human osteosarcoma Saos-2 cells.

NIH RO3 CA94248-01 (Gupta, PI) 04/01/2002-03/31/2005

Prostate Cancer Chemoprevention by Apigenin

The major goal of this proposal was to investigate the cancer chemopreventive and chemotherapeutic properties of apigenin, a widely distributed plant flavonoid on prostate cancer in athymic mouse xenograft model.

NIH RO3 CA99049-01 (Gupta, PI) 10/01/2002-09/30/2005

Inhibition of Prostate Carcinogenesis by Apigenin

The major goal of this proposal was to investigate the cancer chemopreventive and chemotherapeutic potential of apigenin in a transgenic mouse model of prostate cancer.

Cancer Research Foundation of America (Gupta, PI)

01/15/2003-10/14/2005

Apigenin in Prevention of Prostate Cancer

The major goal of this proposal was to investigate the cancer preventive effects of apigenin by modulating cell cycle and apoptotic machinery of prostate cancer cells in *in vivo* model.

DAMD17-00-1-0527 (Mukhtar, PI and Gupta, PI for 3 months)

03/01/02-06/30/02

Green Tea in Prevention and Therapy of Prostate Cancer

The major goal of this project was to define the effectiveness and mechanism of green tea against prostate cancer in transgenic mouse model of prostate cancer.

Cancer Research Foundation of America (Gupta, PI)

10/15/00-09/14/01

COX-2 Inhibition: A Novel Approach for Prostate Cancer Chemoprevention

The major goal of this project was to investigate whether COX-2 inhibition plays a major role in the development of prostate cancer.

The O-CHA(Tea) Pioneer Academic Research Grant Program (Gupta, PI) 10/01/00-09/30/01

Prostate Cancer Chemoprevention by Green Tea

The major goal of this project was to study the health-promoting benefits of green tea in the prevention of prostate cancer.